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Abbrevations 
ALT  Alanine aminotransferase 
ANOVA Analysis of variance 
AST  Aspartate aminotransferase 
ATP  Adenosine triphosphate 
CRRT  Continuous renal replacement therapy 
CI  Cardiac index 
CVP  Central venous pressure 
DAMP Danger-associated molecular pattern 
DC  Dendritic cell 
DO2  Oxygen delivery  
ERC  Endoscopic retrograde cholangiography 
ICU  Intensive care unit 
IL  Interleukin 
IR  Ischemia and reperfusion 
IRI  Ischemia and reperfusion injury 
kDa  kiloDalton 
H+  Hydrogen ion or proton  
HAT  Hepatic artery thrombosis 
LSEC  Liver sinusoidal endothelial cell  
MAP  Mean arterial pressure 
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MWCO Molecular weight cut- off 
NAD+  Nicotinamide adenine dinucleotide (oxidized form) 
NADH Nicotinamide adenine dinucleotide (reduced form) 
NF-ĸB  Nuclear factor kappa-B 
NO  Nitric oxide 
OLT  Orthotopic liver transplantation   
PAMP  Pathogen-associated molecular pattern 
PCO2  Partial pressure of carbon dioxide 
PCR  Polymerase chain reaction 
PRR  Pattern recognition receptor 
PSC   Primary sclerosing cholangitis 
PDH  Pyruvate dehydrogenase 
PMN  Polymorph nuclear neutrophiles 
RNS  Reactive nitrogen species  
ROS  Reactive oxygen species 
TEG  Thromboelastography 
TLR4  Toll-like receptor 4 
TNF-α  Tumour necrosis factor- alpha 
UW solution University of Wisconsin solution  
VO2  Oxygen consumption 
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Definitions 
Cut off  The pore size of the microdialysis membrane described as the molecular 
   weight in Daltons that can pass the semi-permeable membrane 
Ischemia  Blood supply insufficient to maintain aerobic metabolism  
IRI   The inflammation and thereby damage occurring when a tissue is  
  reperfused after a period of ischemia 
Microdialysate The fluid that is recovered over the semipermeabel microdialysis  
membrane from the interstitial fluid  
Microvial  Plastic vial for collection of microdialysate 
Recovery  The ratio between the concentration of a substance in the  
   microdialysate and the interstitial concentration 
Reperfusion  Return of blood supply to a tissue that has sustained an ischemic   
 period 
 
Erratum               
p. 15 line 10:  «and» should be deleted  
p. 15 line 11: increases 
p. 18 line 12: «with» should be deleted  
p. 19 last line:  «with» should be inserted after «treatment» 
p.  20 line 12 and 13: the sentence ”HAT has a mortality rate of approximately 30%, whereas 
for portal vein thrombosis the mortality is 70%” is written twice. 
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p. 24 line 18: «of» should be inserted before «a multitude of…» 
p. 31 line 7: enters  
p. 33 line between line 19 and 20: a ”4” should be deleted 
p.51 line 11 ”membranes” should be inserted after ”cut off”. 
Reference 4: First author is Daniel De Backer, not "De BD". 
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Introduction 
After major surgery like transplantations, robust tools to monitor and detect occult 
deterioration in organ function are crucial. Compromised perfusion or inflammation may 
threaten organ function and thereby the whole organism. Patients may for different reasons be 
in danger of ischemia (trauma, occult bleeding, thrombosis, insufficient vascular anastomosis, 
hypovolemia, hypoxia and infections). The transplanted patient is in addition threatened by 
immunologically incidents and severe graft rejection. All transplant procedures include 
ischemia-reperfusion injury (IRI) and may trigger activation of an inflammatory 
posttransplant reaction that may vary from hardly measurable to organ primary non-function.  
Clinical monitoring is today based on systemic parameters like arterial and central venous 
blood pressure (CVP), pulse frequency, systemic oxygen saturation and preload/fluid 
responsiveness (1;2). These parameters, however, do not reflect regional and microvascular 
organ blood supply or cellular function. The redistribution of blood flow during hemorrhage 
gives priority to brain and heart which may lead to “silent ischemia” in visceral organs (3-7). 
The liver, intestine and the kidney may be severely hypoperfused, but this may not be 
reflected by whole body hemodynamics or systemic blood samples.  
Orthotopic liver transplantation is now an established procedure in the treatment of patients 
with irreversible liver diseases with no other possible treatment option (8). Due to better 
surgical techniques, recent developments in anesthesiology and intensive care treatment and 
more effective immune suppression/anti-rejection treatment, the one year survival in Europe 
has reached 82% (graft survival 75%) and five-year survival 71% (graft survival 63%) (9). 
The respective patient survival numbers for Norway are 90% and 83% (10). In 1980 the one-
year survival was 28 % worldwide (11)! 
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Despite this progress, acute rejection is encountered in about 30% - 60% of the patients 
(12;13), and too many grafts are still lost because of vascular complications like hepatic artery 
thrombosis, biliary complications, infections, primary non-function of the transplant, 
recurrence of the primary liver disease and chronic rejection (14) leading to retransplantation 
or death.  There is an obvious need for more specific diagnostic tools to detect these major 
complications to save as many grafts as possible. 
 
Background 
 
Energy formation from aerobic and anaerobic carbohydrate 
metabolism  
The energy released by the breakdown of glucose is 
chemically transformed into molecules of 
adenosine-tri-phosphate (ATP) by a series of 
enzyme-dependent processes through glycolysis, 
the citric acid cycle (Krebs cycle) and the electron 
transport chain (see figure 1). All cells can use 
glucose as its energy substrate, and some cells (for 
instance liver, myocardial and skeletal muscle cells) 
can also utilize lactate, ketones and fatty acids.  
The glycolytic pathway from glucose to the 
intermediate pyruvate provides a rapid but small 
amount of energy, i.e. 2 ATP molecules per 
molecule of glucose. If oxygen is present, pyruvate is further decarboxylated through different 
steps of the citric acid cycle to the end products water and carbon dioxide. For each round in 
the Krebs cycle two CO2 molecules are released, while one proton and two electrones are 
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glycolysis, Krebs cycle and electron 
transport chain 
 14 
transferred to NAD+. This transfer of electrons into the electron chain is a very efficient 
process that provides 36 molecules of ATP per glucose molecule. The last step of the 
metabolic chain, where NADH is oxidized to NAD+, takes place when oxygen is present. To 
prevent NADH from accumulation in lack of oxygen, pyruvic acid is reduced to lactic acid. 
The toxic co-factor NADH is hereby converted to NAD+ which enables the glycolysis to 
continue when the Krebs cycle and electron chain transport is halted. So, the amount of ATP 
produced under ischemic conditions is small enabling the cells to survive only for a short 
amount of time. In brain cells this give energy for approximately five minutes of no flow. In 
skeletal muscle there are energy reserves like creatine phosphate that can produce ATP and 
keep the muscle alive for 4 – 12 hours. Heart cells die within 30 - 45 minutes of lack of 
oxygen, the liver, kidney and intestine sustain approximately 30 – 60 minutes (15). 
 
Metabolism during ischemia 
The accumulation of lactic acid under anaerobic conditions rapidly leads to an intracellular 
acidosis. Since anaerobic metabolism does not provide sufficient amount of ATP, the cells 
will rapidly consume their ATP which further contributes to the acidification.  
The cells would be destroyed if the acidification was not limited by effective intracellular 
buffer systems. The most important buffers are proteins and bicarbonate and to a lesser extent 
inorganic phosphate.  It is mainly the amount of histidine that determines the buffer capacity 
of proteins. Histidine is the only amino acid with pKa near physiological pH. Because of the 
higher concentration of proteins intracellularly compared to plasma and the interstitium, the 
buffering of protons by proteins inside the cell is greater than outside (16). 
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The protons liberated during anaerobic 
metabolism also react with HCO3- and 
form CO2 and H2O. Except for nerve cells 
with a high electric resting potential, 
skeletal muscle and myocardial cells with 
a lower intracellular HCO3-, the 
concentration of HCO3- is about the same 
intracellularly and extracellularly. The 
ability of CO2 to pass cell membranes and 
be and carried away and be expired by the 
lungs increase the buffer capacity of 
HCO3- substantially. During ischemia, 
however, when blood supply is limited, 
CO2 will  accumulate in the tissues. This 
is the basis for using CO2 to diagnose 
intracellular acidosis and ischemia (17). 
CO2 diffuses through the cell membrane 
according to the transmembrane gradient 
so measurements of PCO2 in the interstitium, on the surface of solid organs, or inside the 
intestinal lumen correlate well with the intracellular PCO2. 
Even a moderate reduction in blood flow and thereby reduced DO2 are compensated by 
increased O2 extraction to maintain normal cellular functions. The oxygen consumption (VO2) 
under aerobic conditions is termed ”supply independent”. Below a “critical” level, defining 
the anaerobic threshold, however, the tissues are no longer able to compensate by increased 
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Figure 2: The relation between oxygen consumption 
and oxygen delivery in an organ follows a dual line. 
Due to increased oxygen extraction moderate decreases 
in oxygen delivery will not change the oxygen 
consumption. When blood flow becomes seriously 
reduced, additional reductions in oxygen delivery lead 
to a rapid drop in oxygen consumption (Figure used 
with permission from Acta Anaest Scand). 
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extraction, the consumption (VO2) has become “supply dependent” and decreases linearly 
with the reduction in DO2 as demonstrated in figure 2 (18). 
Increased oxygen extraction allows each volume unit of venous blood to receive more CO2 in 
return. Thus, even a moderate reduction in the organs blood supply will increase venous 
PCO2. Since there is a PCO2 gradient from the tissue to venous blood, an increase in venous 
PCO2 occurs concomitantly with an increase in tissue PCO2. 
 
Parameters for intraorgan monitoring of ischemia 
Systemic calculations of VO2 and DO2 are inadequate in detecting occult tissue hypoxia in 
critically ill patients. Tissue gazes like PCO2 and PO2 reflect ischemia. It can be measured 
directly in expired air, in arterial and venous blood, intraluminally in gastrointestinal tractus, 
on the surface of solid organs or directly in tissues of interest. 
Gastric tonometry, monitoring mucosal PCO2 and pH, can detect occult hypoperfuson and 
tissue hypoxia and predicts outcome in critical illness (19). It was enthusiastically introduced 
in the clinic 20 years ago, but due to a cumbersome methodology and problems with 
positioning the balloon, digestion of food, levels of gastric acid and bacterial CO2 production 
leading to erroneous readings (20), it has not gained widespread use. The tonometer has a gas 
filled silastic balloon introduced into the gastrointestinal tract, most often in the ventricle. The 
air inside the balloon equilibrates with the surrounding CO2 gas so PCO2 measurements of the 
sampled air will reflect intramucosal PCO2 (21). The more recent PCO2 optode Neurotrend 
has also been tested in several experimental and clinical settings, but is no longer 
commercially available.  
Sublingual capnography applies an optode for PCO2 measurement and a temperature sensor 
placed under the tongue (22). It measures PCO2 reliably compared to the tonometry method 
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(23), but was recalled due to serious infections probably caused by bacteria in the solution 
where the probes were stored. More convenient methods of PCO2 measuring is warranted, 
and lately, our group has invented a novel PCO2 device for tissue monitoring (24;25). 
The documentation on intraorgan monitoring of glucose metabolism using the microdialysis 
system both experimentally and clinically is growing (26;27).  
As described above, hypoxic cells become dependent upon the anaerobic breakdown of 
glucose for production of ATP. This causes an increased conversion of pyruvate to lactate. A 
lactate/pyruvate (LP) ratio >20 can has thus been used as a marker of ischemia (28). The LP 
ratio has the advantage of abolishing changes in recovery over the dialysis membrane. Tissue 
glucose, being the main substrate for energy production, may also provide valuable 
information. With a reduced blood flow and supply of glucose the tissue levels will rapidly 
decline.  
Glycerol is an integral component of the cell membrane and reflects how severely the cells are 
deranged. Loss of energy leads to an influx of calcium and activation of phospholipases that 
split the glycerol backbone from the phospholipids.  
 
Liver transplantation  
In Europe more than 5000 liver transplantations are carried out each year.  In Norway the 
transplantation activity is centralized to Oslo University Hospital, Rikshospitalet with 
approximately 100 transplants a year (10).  
In Europe the most common liver diseases leading to transplantation (9) include cirrhosis 
(58%), (including hepatitis C, alcoholic cirrhosis, autoimmune diseases and primary 
sclerosing cholangitis (PSC)), cancer 14%, cholestatic disease 10%, acute liver failure 9%, 
metabolic disorders 6% and others 3%. In the Nordic countries, PSC is the most common 
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indication for liver transplantation (29). Patients with hepatocellular carcinoma and selected 
patients with liver metastasis are now more often offered transplantation (30). 
The mentioned diseases may lead to complications like variceal bleeding, ascites, hepatorenal 
syndrome, hepatic encephalopathy, recurrent infections, e. g. spontaneous bacterial peritonitis 
or bile duct stenosis. 
After organ transplantations early detection of compromised organ function is highly needed, 
both because of the shortage of available organs but also due to the dramatic and not seldom 
fatal complications (31). 
 
The transplantation procedure  
In patients where the clinical evaluation indicates brain death, an angiography will verify lack 
of cerebral circulation and the patient can then be considered a potential organ donor. Split-
liver transplants with are performed in about 20% of transplantations at our hospital, while the 
use of living donors is not established as a routine.  
Pre transplantation blood samples from the donor are analyzed. In contrast to other organ 
transplantations HLA-typing is not necessary in liver transplantation. The donor is treated to 
maintain physiological tissue perfusion and optimal organ function. 
The harvested liver is stored in a cold preservation fluid (University of Wisconsin solution = 
UW solution) (32), to slow down the metabolism. The UW-solution contains lactobionate and 
raffinose to suppress the hypothermia induced cell swelling, potassium to reduce loss from the 
cells and the antioxidant gluthation.  
The liver is removed and replaced by the donor graft with vascular and biliary anastomoses. 
During the procedure now more often the ”piggy back” method is used where the patients’ 
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caval vein is only partially occluded, and no bypass is needed (33), while in complicated 
cases continuous veno-venous bypass is still used. 
It may take from 6 to 24 hours from the donor liver is harvested until it gets perfused in the 
recipient. In this period the donor organ is not circulated and receives no oxygen or nutrition. 
Despite the slow metabolism and low energy requirements following cooling and perfusion 
with UW solution, cold storage more than 12-15 hours increases the incidence of graft 
dysfunction significantly (34). From the time the donor liver is removed from the cold 
preservation and transplanted into the recipient, it is subjected to ”warm ischemia”. In general 
cold ischemia seems to cause more damage to nonparechymal cells, i.e. Kuppfer and liver 
sinusoidal endothelial cells (LSEC) and to trigger immunologic activity. Warm ischemia 
interferes more with the hepatocytes and thereby the metabolic functions (35). The cold and 
warm ischemia time following a transplantation has a detrimental and synergistic effect on the 
liver graft (36) so it is important to minimize the duration of both the cold and warm ischemia 
(34;37). 
 
Complications in liver transplantation 
Complications after liver transplantation may be divided into medical, technical, and 
immunological entities (14). 
A compromised preoperative condition, often seen in patients on “urgent call” (acute liver 
failure) as well as preoperative mechanical ventilation, render the patient more susceptible to 
complications. 
Postoperatively the medical complications include bacterial (pneumonia, cholangitis, sepsis), 
viral or fungal infections. Toxicity related to immune suppression (nephrotoxicity following 
treatment a calcineurin-inhibitor or thrombopenia with mychophenolate or rapamycin) are 
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common complications. Acute kidney injury and renal failure, initially poor functioning grafts 
or even primary nonfunctioning grafts are other complications during the postoperative 
course. 
The technical complications postoperatively are most often associated with biliary leakage or 
stricture/stenosis and occur in 11 to 25 % of cases (38). Biliary complications are in general 
managed endoscopically or by other less invasive methods. Untreated, however, they may 
lead to graft dysfunction and infections. 
Vascular complications are a major threat to the liver graft and must be detected early to 
avoid graft loss. Hepatic artery thrombosis (HAT) is seen in about 3 – 6 % of the patients, but 
is more frequent, about 6 - 10% in children. Portal vein thrombosis is seen in about 1 – 3 % of 
patients (39). HAT has a mortality of approximately 30%, whereas for portal vein thrombosis 
the mortality is 70% (40). HAT has a mortality of approximately 30%, whereas for portal vein 
thrombosis the mortality is 70%. Methods for early detection of vascular complications are 
therefore needed. Postoperative hemorrhage is either due to insufficient surgical hemostasis, 
bleeding from insufficient vascular anastomosis or coagulopathy. 
The immunological complications include acute and chronic rejection. The acute rejection to 
liver grafts is most often milder and responds better to treatment compared with rejections to 
kidney and heart grafts (12). 
Chronic dysfunction is, however, most often related to recurrence of the primary disease, 
especially for patients with hepatitis B and C and patients with primary biliary cirrhosis 
(PBC). 
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Present perioperative monitoring and management 
Patients undergoing a liver transplantation are invasively monitored. The arterial, central 
venous and pulmonary artery catheters allow continuous measurements of the systemic 
circulatory status.  
Because the patient preoperatively may be critically catabolic and deranged, reestablishing a 
positive energy balance is crucial. It is essential that the patients get enough carbohydrates the 
first days so further breakdown of proteins are reduced. After a few days the patient most 
often can turn to a normal balanced diet. Insulin may be necessary to control the blood sugar 
levels during the first days after transplantation. 
During surgery a transit time ultrasound probe is placed around the portal vein and the hepatic 
artery to assess hepatic blood flow. Doppler examination is performed once or twice during 
the next postoperative days, and later on if indicated. It has been demonstrated that hepatic 
artery flow predicts survival of the liver graft (41). Characteristic changes are revealed by the 
Doppler examination in hepatic artery thrombosis (HAT) with a high (0.8-0.9) resistive index 
(RI) and a prolonged systolic acceleration time (SAT). With acute graft rejection there may be 
a marked decrease in portal blood velocity and an increase in splenic pulsatile index (42-46). 
In uncomplicated cases transplanted patients stay one or two days in the ICU, thereafter two 
weeks on the surgical transplantation ward before transferal to a medical ward. Some patients, 
however, need a prolonged recovery time either due to preexisting conditions, intraoperative 
events or postoperative complications (47). 
Blood samples are analyzed daily for blood cells, glucose, electrolytes, coagulation status, 
liver and renal function. Patients with a manifest hepatorenal syndrome or renal failure due to 
the immune suppressive treatment may need continuous renal replacement therapy (CRRT), 
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due to overhydration and/or electrolyte disturbances and meticulous monitoring of the fluid 
balance is mandatory.  
Increasing thrombocyte counts indicate adequate liver function while persistent high INR 
levels may be a sign of a non-functioning graft.  
The immune suppressive treatment renders the transplanted patients in danger of 
opportunistic infections.  Screening for cytomegalovirus (CMV) infection is therefore 
performed every week the first three months. Trimethoprim sulfa is given routinely to protect 
against pneumocystis carinii, while patients at particular risk are also given antifungal 
prophylaxis. 
Postoperative increases in liver enzymes may indicate cell injury during the preservation 
period or ongoing liver ischemia (circulatory failure). Increasing values of bilirubin may 
indicate biliary occlusion or rejection. Ultrasound Doppler, hepatic angiography, endoscopic 
retrograde cholangiography (ERC) or even surgical intervention may be necessary. 
 
Graft rejection - present diagnostic tools and treatment 
Symptoms of rejection may be fever and abdominal pain, and a rise in transaminases are 
regularly found. A slowly increasing bilirubin may be seen, but the patient may have only a 
few symptoms. Diagnosis is verified by liver biopsy.  
It is important to diagnose rejection as soon as possible to start appropriate anti-rejection 
therapy. Standard immune suppressive induction therapy starts with a triple combination with 
corticosteroids, calcineurin inhibitor (CNI) to inhibit the activation of T-lymphocytes and 
thereby the synthesis of IL-2 and the expression of the IL-2 receptor on the cell membrane 
and mycophenyl mofetil with effect on both B and T-lymphocytes. Tacrolimus has replaced 
cyclosporine as the CNI drug of choice. The doses of CNI are kept low because of the danger 
for renal injury. Patients with, or at risk of developing renal failure, are given delayed start 
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with CNI and induction treatment with basiliximab, a monoclonal immunoglobulin that binds 
to activated T-cell receptor for IL-2 is prescribed. This drug combination is used to achieve a 
strong and immediate effect to prevent acute rejection. The dosages are thereafter gradually 
reduced as the graft inflammation subsides (48). 
When rejection has been verified histologically, treatment with high doses of corticosteroids 
is started. In some cases the CNI dosages are increased or monoclonal antibody muromonab 
CD 3 (OKT-3) is initiated that specifically reacts with the T-cell receptor CD-3 complex and 
thereby blocks the activation of T cells.  
 
The ischemia-reperfusion injury in liver transplantation  
Following transplantation with periods of cold and warm ischemia, IRI is inevitable. The graft 
has prior to transplantation been exposed to an inflammation triggered by the brain death. 
During the ischemic periods and the following reperfusion the inflammation are further 
activated. 
Several studies have been performed trying to unravel the mechanisms involved in this IR 
injury (49-61). Liver IRI involves activation and cooperation of both cellular and humoral 
mechanisms. Main cellular contributors are dendritic cells, CD4+ T-cells, Kuppfer cells, 
hepatocytes and neutrophil leucocytes (PMN). Humoral substances include the complement 
proteins, cyto- and chemokines communicating between the cellular components (49). 
Microvascular endothelial cells are active participants and regulators of the inflammatory 
process (62;63), and effects on the hepatic microcirculation is essential in IRI (64). The length 
of the cold ischemic period has been shown to increase cell membrane damage and sensitize 
the graft for rewarming injury during reperfusion (65). Increased blood levels of liver 
transaminases (AST/ALT) are used to evaluate the degree of liver injury.  
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Paradoxically, although reperfusion of the ischemic graft is mandatory for its function and 
survival and limits the ischemic destruction, it increases the damage caused by the ischemia 
and causes even more cellular injury. 
Injury to the allograft gives production of reactive oxygen species (ROS) which not only 
cause cellular damage but also release of intracellular agents that act like damage-associated 
molecular patterns (DAMP)s. The heat shock proteins and mitochondrial DNA, for instance, 
act as danger signals when getting out of the cell (66) most in the same way as pathogen-
associated molecular patterns (PAMPs) such as endotoxin. These substances act as ligands on 
different receptors and activate the innate immune system via Toll like receptors  (TLR4 best 
described) that is a Pathogen Recognition Receptor (PRR) mainly on dendritic and Kupffer 
cells and further recruit activated neutrophils and monocytes to the liver (57). 
The activation and upregulation of inflammatory mediators may be used diagnostically in 
estimating the degree of IRI, so far most in experimental settings. Many inflammatory 
substances like cytokines are expressed in IRI (67). 
CXC-chemokines and especially CXCL-10 (IP-10) act as chemoattractants for leucocytes and 
are produced via TLR-4- IRF-3 (Interferon regulatory factor 3) activation pathway. It plays a 
role in  the immune response of IRI and in an experimental model inhibition reduces the IRI 
(61;68). The IRI is also a strong inducer of complement activation that leads to production a 
multitude of inflammatory mediators (69-71).  
 
Rejection of the transplanted liver graft 
 Although the first liver transplantation with a graft from a non-related donor was performed 
as early as in 1963, it was not until the discovery of the immune suppressive effect of 
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cyclosporin (approved for clinical use in 1983) that organ transplantation, including liver 
transplantation became an established clinical treatment for end stage organ failure. 
When transplanting organs between genetically different individuals, a T-cell mediated 
immune response is initiated which may result in destruction and rejection of the graft (59). 
To prevent such an outcome the patient receives induction therapy with a combination of 
immune suppressive drugs that reduces this initial immune response.  
Histologically, liver allograft rejection can be divided into three categories (12). In the 
hyperacute rejection (massive hemorrhagic necrosis), there is an anti-donor humoral immune 
response leading to depositions of antibodies, platelets, fibrin and erythrocytes within the 
portal venules and hepatic sinusoids. This has been seen after transplantation with preformed 
antibodies in ABO incompatible combinations although some liver transplantations with A2 
donors and 0 recipients and even other ABO incompatible combinations have been 
successful.  
In acute rejection (also known as cellular) bile duct inflammation and venular inflammation 
are seen. Lymphocytes are infiltrating the portal triads. Early acute rejection (earlier than 3 
months) responds in general well to increased doses of immune suppressive drugs.  Late 
acute, recurrent and steroid-resistant rejections, however, are more difficult to treat. 
Chronic rejection (ductopenic) is characterized by loss of bile ducts, persistent inflammation 
and arterial foam cell infiltration and is more often associated with graft loss. 
A criteria system has been developed to score liver allograft biopsies with acute rejection 
based on portal inflammation, injury to bile-ducts and degree of inflamed endothelial cells in 
liver veins. Each category of the rejection injury is graded in a scale from 0-3 giving a 
rejection activity index (RAI) from 0-9.  
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Graft versus host disease (GVHD) is a rare complication after liver transplantation. T-
lymphocytes from the donor attack organs and tissues in the recipient. With HLA-typing these 
T-lympocytes can be demonstrated histologically by biopsies from the skin. 
An acquired tolerance to the transplanted organ, without life-long use of immune suppression 
develops in some patients, mostly in children, in particular those transplanted under the age of 
one year. The microenvironment of the liver can promote tolerance to a much higher degree 
than other organs. Normally, the immune system and the liver show tolerance to self-antigens. 
The hepatic sinusoidal system is exposed to food-derived and bacterial antigens, absorbed 
from the alimentary tract transported to the liver via the portal vein. The exposure normally 
leads to immunological tolerance rather than immunity of the T-cells to antigens that are not 
regarded as dangerous to the organism. The liver is thus less prone to rejection and immune 
mediated injuries than organs like kidney and heart. Acute rejection is influenced by the 
donor and recipient’s antigen composition or degree of foreignness. Donor HLA-antigens are 
presented to the host T cells. This is done via indirect allo-recognition, where endocytosed 
material, i.e. HLA-molecules from the transplanted graft, or fragments of these are captured 
by the recipients antigen presenting cells (APC’s) (dendritic cells (DC), Kuppfer cells, 
sinusoidal cells, and hepatocytes. In direct allorecognition, antigen material is presented to T-
lymphocytes via APC from the donor graft. When the activated APCs are presented for the 
recipients T-cells , activated T cells are “educated” and recruited into the graft which result in 
tissue damage. The degree of IRI injury described earlier may have an influence on rejection, 
although an overwhelming IRI may first of all lead to a primary non-fuctioning or poorly 
functioning graft. Central to the inflammatory response is further promotion of reactive 
oxygen species (ROS) and stimulation of the innate immune system and maturing of dendritic 
(DCs) and other immunological active cells, leading to increased production of inflammatory 
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mediators and activation of the adaptive immune system which, via CD4+ T-cells lead to the 
allograft rejection (53;56).  
Immune suppressive treatment has serious long-term side-effects including development of 
posttransplant lymphoproliferative disease (72) and cancer. Earlier, episodes of acute 
rejection were treated with more aggressive immune suppression, a treatment which later was 
associated with chronic rejection (12). Aggressive immune suppressive treatment targeted not 
only the cytotoxic T-cells, but also the regulatory T-cells (Tregs, which actually are T cells 
expressing both CD4+ CD25+) that probably play a crucial role in development of tolerance 
(59;73).  In  the “decision” between tolerance or immunity and rejection, different cytokines 
modulate alloresponsive T-lymhocytes to either develop a proinflammatory response ending 
in graft destruction or a tolerogenic response resulting in graft acceptance (74). 
Today, there is a tendency towards less aggressive immune suppressive regimes.  Although 
this may lead to more episodes of acute rejection, the incidence of late rejections and graft 
loss has decreased. With milder immune suppression regimes, recruitment of and generation 
of Tregs will develop as part of an acute rejection reaction, leading to a better tolerance to the 
graft. In fact, it has been shown that some patients can manage without any immune 
suppression at all (75). Strategies to predict which patients do not need such treatment, is a 
challenging task. During acute rejection in liver transplant patients it has been demonstrated 
decreased levels of circulating CD4+_CD25+ Tregs (76). The inflammatory donor mediator 
IP-10 and recipient mediator CXCR-3 have shown to play a role in initiating acute rejection 
in a heart transplantation model (77-79). IP-10 has also been shown to predict fibrosis 
progression after liver transplantation for Hepatitis C infection (77). Increased complement 
activation is documented in liver transplant rejection (80-83), and has been associated with 
poor graft functioning (84). IL-2 is produced during rejection (85) and has been used as a 
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response measure for the anti-rejection treatment. Elevated levels of IL-8 in biopsies (86) and 
in blood (87;88) have also been reported during rejection. 
 
Aims of the work 
The main aim of our research group has for several years been developing and evaluating 
implantable microdevices for detection of ischemia, both in experimental animal models and 
clinically. Study 1 in this thesis is a study with this aim. In an experimental porcine model we 
conducted a study with a progressive hemorrhagic model to compare different methods of 
ischemia detection, to characterize the effect of ischemia on different organ systems (liver, 
kidney, intestine and skeletal muscle) and to define the transition from aerobic to anaerobic 
metabolism. 
Through this hemorrhagic study we explicitly gained experience with the microdialysis 
system as a reliable method to monitor and describe renal, hepatic and intestinal and muscular 
glucose metabolism under ischemia with the intermediate metabolic parameters glucose, 
pyruvate, lactate, LP ratio as well as glycerol. Based on this work, where we reliably detected 
ischemia in liver, we wanted to investigate whether microdialysis could be used to detect 
ischemia in a clinical setting, namely in monitoring transplanted livers in the immediate 
postoperative period (first week). Since there is a clinical need to detect ischemia caused by 
hepatic artery or portal vein obstruction as soon as possible to save the graft, we learned from 
the animal study that ischemia was reliably detected within 1 hour so implementing hourly 
measurements would detect ischemia earlier than current methods.  
Microdialysis in human liver transplantation had been done in pilot studies for metabolic 
monitoring (89;90). In addition to monitoring ischemia we wanted to explore whether the 
microdialysis system also could be used to monitor immunological inflammatory parameters 
(cytokines and complement activation). In a methodological in vitro study we therefore 
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explored the ability of the microdialysis systems to recover relevant immunologic 
inflammatory parameters using a microdialysis catheter with a 100 kD pore size. The 
microdialysis system in transplanted liver grafts for monitoring cytokines and complement 
activation had not been tested in clinical studies.  Based on the experience with microdialysis 
in the experimental studies (paper I and II) with metabolic intermediates and inflammatory 
mediators we initiated a study on liver transplanted patients, expanding the use of 
microdialysis to also include monitoring of immunological inflammatory parameters in 
addition to metabolic parameters. We wanted, by way of selected inflammatory and metabolic 
parameters to characterize the postoperative course in patients without complications and to 
explore whether ischemia or transplant rejection could be detected, and if that was the case, 
would complications be detected earlier with microdialysis than with standard monitoring. 
The results could have implications on how we routinely monitor liver transplanted patients. 
 
Paper I 
In this experimental porcine study on hemorrhagic shock, we aimed to: 
 Characterize hemodynamic responses in different organ systems when cardiac index is 
reduced by hemorrhage. 
 Study gas tensions, acid base variables and metabolic intermediates in skeletal muscle, 
kidney, liver and intestine during progressive hemmorhage.  
 Compare PCO2 to metabolic parameters of ischemia for their ability to detect 
hypoperfusion and ischemia. 
Paper II 
In this in vitro study we aimed to: 
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 Determine the in vitro recovery of cytokines like TNF-α, IL-1b, IL-6 and IL-10, the 
chemokines IL-8, MCP-1, IP-10 and MIG and the complement anaphylatoxins C3a, 
C4a and C5a, using reference preparations with known concentrations of the analytes.  
 Compare recovery rates through microdialysis membranes with two different 
molecular weight cut offs (20 kDa and 100 kDa) at different flow rates (0.3,1 and 5 
μl/minute). 
Paper III 
In this clinical study where microdialysis catheters were inserted in the liver and 
subcutaneously peroperatively, and kept in place for 7 days, we aimed to: 
 Characterize the pattern of lactate, pyruvate, glucose and glycerol and relevant 
inflammatory substances like cytokines and parameters of complement activation in 
patients with a normal postoperative recovery 
 Explore whether microdialysis with a 100 kDa cut off filter could be used to detect 
liver ischemia, rejection or other complications after allograft liver transplantations. 
 
Materials and methods  
 
Biosensors for tissue gas monitoring 
Three different biosensors were used: An electrochemical sensor (MI 720 Microelectrodes, 
Bedford, NH, USA) measuring PCO2, a Clark-type sensor for oxygen tension measurements 
(Licox™) and a multisensor device, Neurotrend™, using optical sensors for the measurement 
of pH, PCO2, and pO2. 
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PCO2 measurements based on a modified electrometric pH electrode  
The Severinghaus sensor is a modified electrometric pH electrode measuring 
tissue PCO2 (91) It consists of a glass pH sensor within a chamber which at 
the tip is covered with a Teflon membrane permeable to gases including CO2. 
In the space between the glass surface and the membrane there is an aqueous 
medium of 5 mM bicarbonate buffer. 
Through the gas permeable Teflon membrane CO2 enter the bicarbonate 
solution. The following change in pH is detected by the pH sensor. PCO2 is 
calculated according to the linear relationship between log PCO2 and pH.  
The Severinghaus PCO2 sensors were calibrated by a three point calibration 
with PCO2 tensions from 3 to 25 kPa. The values were checked by a blood 
gas analyzer just before and just after the experiment and drift was corrected. 
The sensors were inserted into the intestinal lumen or placed on the muscular 
surface. To avoid injury to the muscular tissue and prevent gas evaporation 
the electrodes were placed in rubber gaskets with the tip placed 0.5 mm from 
the surface.   
  
Multiparameter sensor (Neurotrend™) 
The Neurotrend™ sensor is a disposable, single-use device for the continuous measurement 
of tissue pH, PCO2, PO2, and temperature. While the pH and PCO2 sensors work on the 
principle of optical absorption, the pO2 sensor apply the principle of fluorescence quenching, 
whereby the intensity of a fluorescent optical emission from an indicator is reduced in the 
presence of oxygen. The diameter of the probe is 0.5 mm and the four sensing components are 
Figure5: The 
Severinghaus 
–type sensor 
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located at different intervals along the distal 4 cm of the polyethylene probe which is 
permeable for O2 and CO2. The outer surface of the probe is coated with covalently bonded 
heparin to prevent fibrin deposition. The flexible wire part of the device has a length of 600 
mm. The Neurotrend sensors were calibrated before use in a separate calibration unit 
(Diametrics Medical). This unit is also used for data capturing and storage. Values of pH, 
PCO2, pO2, and temperature were recorded every 60 second. 
 
Clark-type sensor for Oxygen Tension Measurements (Licox™) 
To monitor oxygen tension levels directly we used a miniaturized Clark-type sensor which 
can be inserted into the tissue (Licox, Integra, Germany). The sensor is calibrated with a one 
point calibration in air before use. This sensor is 0.7 mm in diameter and contains a silver 
anode and a platinum cathode which is covered by a membrane that is oxygen-permeable. A 
constant voltage is applied to create a reaction between oxygen and the platinum electrode. 
The drained current between the two electrodes is proportional to the tension of the oxygen in 
the tissue. 
 
Animals used in study I 
Before the commencement of this study, we discussed carefully if we should include a control 
group and decided not to do so for the following reasons: i) The animals in this study are their 
own controls as the parameters during blood loss are compared to baseline values. Six 
consecutive baseline values were collected during 90 min after surgery, and the animals were 
very stable; ii) we have carried out several studies on models very similar to this one where 
the animals have undergone major abdominal surgery receiving exactly the same anesthesia 
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as in this study and been anesthetized for up to 12 hours after surgery. These animals have 
been very stable and tolerated the procedure without significant changes in organ blood flow 
and have revealed no signs of ischemia. We are therefore convinced that findings in this study 
are due to the bleeding protocol and not to surgery and anesthesia per se; iii) in our institution 
we carry out experiments on more than 200 pigs a year, and we are striving to limit the 
number of animals used as much as possible (both for ethical and economic reasons), and we 
therefore usually only include control animals in the pilot phase or in new types of 
procedures. As the procedure used in this study is nearly equivalent to other studies carried 
out, we reasoned that a control group was not deemed necessary; iv) we know from previous 
studies that the drift of microdialysis, Neurotrend and Licox are minimal and cannot account 
for the changing values over time. The drift in the Severinghaus-type of sensors was taken 
care of by careful calibration with known PCO2 values before and after the experiment and 
the drift was mathematically corrected. 
 
Microdialysis 
Microdialysis is a method for tissue sampling of small molecules based on a passive diffusion 
of substances across a semipermeable hollow fiber dialysis membrane. The microdialysis 
probe is built up as a concentric tube where the perfusion fluid flows through an inner tube to 
the distal end where the direction is reversed. The solution enters the space between the inner 
tube and the dialysis membrane where the exchange of molecules takes place. The difference 
in concentration over the membrane governs the direction of the gradient. A 2.5 ml syringe 
with a perfusion fluid is placed in a portable battery driven pump adjustable for different flow 
rates (0.1–5 μl/min) and connected to the microdialysis catheter. Two different microdialysis 
catheters were used: the CMA 61 20 kDa and CMA 71 100 kDa. The microdialysis catheters 
were inserted into the tissues by a splitable introducer. When starting the battery driven pump, 
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Figure 4: The Microdialysis system. Fluid in the syringe is pumped 
into the microdialysis catheter entering the space between the outer 
and the inner concentric tubes. Exchange of substances takes place 
through the outer membrane. The dialysate then enters the inner 
tube at its distal end and is propulsed into a microvial at the end. 
The accumulated fluid in the microvial can then be analysed 
(figure used with permission from Microdialysis, Stockholm, 
Sweden). 
the perfusion fluid is driven 
through the catheter. The 
solution then equilibrates with 
the surrounding extracellular 
tissue fluid over the 
microdialysis membrane. The 
dialysate is collected in 
microvials connected to the 
catheter. 
 
Application of 
microdialysis in 
studies II and III 
In paper II we investigated 
the ability of microdialysis 
membranes with 20 kDa and 
100 kDa to recover cytokines, chemokines and complement activation factors. Reference 
preparations for cytokines and chemokines were prepared from plasma after incubation of 
human blood with lipopolysaccharide (LPS) and for anaphylatoxins by incubating human 
plasma with heat aggregated immunoglobulin G (HAIGG).  
Microdialysis was performed in these preparations with known concentrations of the relevant 
substances with the two different membranes at three different velocities (0.3, 1 and 5 
µl/min). The mediators were then analyzed with cytometric bead assays.  
In paper III microdialysis catheters were used to monitor immunological mediators in 
transplanted livers. Microdialysis catheters with 100 kDa MWCO were inserted into the left 
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and right liver lobe respectively via a split device, tunneled out through the abdominal wall 
and connected to a CMA107 microdialysis pump. A reference catheter was inserted 
subcutaneously in the lower pectoral area. 
The metabolic parameters glucose, lactate, glycerol and pyruvate, and the calculated ratio 
between lactate and pyruvate, LP ratio were analyzed by the CMA106 Analyzer every hour 
the first 24 hours, thereafter every two hours the next six days. Samples for inflammatory 
parameters were frozen every 4 hours at -70 ºC and analyzed later with the bead assay 
method. 
During removal a small part at the distal end of one the hepatic catheters was left in the 
abdomen as it broke when trying to pull it out. We did not regard it possible or necessary to 
remove this small surgically, which was explained to the patient. The patient did not 
experience of any symptoms or signs related to this foreign body. There were reported similar 
problems in other studies, and the manufacturer withdrew the catheters from the market in 
order to make them more robust. Due to a halt in the production of catheters which lasted 
more than 6 months, we ended inclusion of patients after 20 cases. More than 200 of the new 
catheter have been inserted in the liver at our hospital. None of these have broken during 
removal.  
There were no other complications, for instance bleeding or infection related to insertion and 
use of the catheters. In two cases where patients were reoperated the first postoperative day, 
the catheters were removed and not replaced. In three other patients one of the hepatic 
catheters stopped to function after 2, 3 and 4 days respectively, but since we had one catheter 
in each lobe we were still able to collect data.  
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Analysis of immunologic parameters recovered through microdialysis 
Both in study II and III cytokines and complement activation factors were analyzed using 
cytometric bead assays. In the cytometric bead assay method, beads, each coated with a 
unique cytokine, chemokine or anaphylatoxin detection antibody directed against the 
respective analytes are mixed with the analyte samples. The particles are dyed with different 
fluorescence intensities, separately detected by flow cytometry. The different capture beads 
bind their specific analytes which is then detected by specific antibodies conjugated with 
phycoerythrin present in the buffer solution. 
In study III we used the Bio-Plex Human Cytokine27-Plex Panel kit (Bio-Rad Laboratories 
Inc., Hercules, CA). Here the beads are also coated with cytokine antibodies. When the beads 
are incubated with the samples, a secondary biotin-conjugated antibody is added and then a 
reporter molecule (streptadivin-PE) binds to the biotin. The samples are then further run in a 
modified flow cytometer with two lasers, one which excites the beads and one which excites 
the reporter molecule. In this way, the beads are “separated”, and the amount of each of the 
cytokines can be quantified. 
 
Clinical study (Paper III) 
Patient characteristics  
An important aim of the clinical liver transplantation study was to describe the development 
of metabolic and immunologic parameters both in normal and complicated complicated cases. 
There were 14 patients without major clinical complications during the time the catheters 
were inserted. However, several of these developed complications after removal of the 
catheters as shown in the table below. The following patients were excluded from the normal 
 37 
group: Four patients who underwent rejection during the first nine days (one of them also a 
HAT), one patient an ascending bile-infection and one patient with a non-functioning 
microdialysis catheter. Thus, six patients were excluded from the normal group of fourteen. 
Both retransplants were in the group of excluded patients. The fourteen normal patients were 
also used as the normal population for immunological studies. However we also analyzed the 
three patients described in the paper as patients with complication (case 1 – 3) in the same kit 
batch in order to have comparable results, i. e. avoid batch variations. Since each kit has 80 
wells, we had to exclude 3 normal patients to get space for the complicated ones. We could 
have used another kit for these three patients, but that would give batch variations, and would 
considerably increase the cost. We therefore decided that 11 patients would suffice to get data 
for normal patients.  
As demonstrated in Table 1 below, only 5 out of the 20 patients were actually without any 
registered events or postoperative complications, but the majority of these complications 
occurred after the microdialysis catheters were removed. 
Patient      Diagnosis                     Events/complications 
1 Hyperoxaluria                 Combined liver/kidney tx, rejection of kidney 
2 Cirrhosis, alcoholic             Ascending bile duct infection 
3 PSC                         Biliary leakage 
4 Acute viral hepatitis            Multiple complication including rejection in 
retransplanted  graft, patient died after 6 months 
(Case 2 in paper III) 
5 PSC                         Recurrence, retransplanted x 2 
6 Cirrhosis, Hepatitis C               Recurrence of Hepatitis C   
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7 Bile duct atresia                Initial high resistance in hepatic artery 
8 Cirrhosis, alcoholic 
Hepatocellular Carcinoma  
ALT 4445 IU the first day 
9 Cirrhosis                      Postoperative lung edema 
10 Cirrhosis                      None 
11 Portal vein trombosis            HAT, rejection day 11, catheter 6 days (Case 3 in 
paper III) 
12 Cirrhosis, alcoholic               None 
13 Cirrhosis, unspecific              Catheter broke during removal 
14 Steathosis                      None 
15 PSC                          Recurrence 
16 Hemangioendothelioma         Rejection verified day 7, catheter 11 days (Case 1 
in paper III) 
17 PSC                            None 
18 PSC                         None 
19 Budd Chiari disease  Stenosis of choledochus, rejection verified day 9, 
catheter removed after 5 days 
20 Autoimmune hepatitis            Aspergillus infection, patient died after 5 months 
Table 1. Complications after liver transplantation for patients in study III 
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Statistics  
In study I, baseline values of the variables served as controls. To reduce the effect of transient 
flow variations we calculated replicates as the mean of the two former, the present and the 
two next flow measurements.   
For each ischemia parameter in each organ a critical cardiac index value, CI crit, was 
determined by dual line regression analysis (92). 
All variables are presented as median with interquartile range (25% - 75%). Areas under the 
flow curves (AUC) were calculated using the sum of rectangles method. To determine 
significant differences between the critical values, the non-parametric methods Kruskal-
Wallis One Way Analysis of Variance on Ranks and Post-hoc Student-Neuman Keuls (SNK) 
test for a multiple comparison of all the groups were used.  
Time derivates of PCO2 and lactate, dPCO2/dT(time) and d[lactate]/dT for the investigated 
organs were calculated to show differences in the rate of increase  under aerobic and 
anaerobic conditions. The Kruskal-Wallis One Way Analysis of Variance on Ranks and Post-
hoc Student-Neuman Keuls (SNK) test for a multiple comparison of all the groups were used 
In study III data are shown as median with 25 and 75 quartiles. We used a Wilcoxon rank sum 
test to decide differences between values from liver and subcutaneous tissue (in paper III it 
erroneously says Wilcoxon signed rank test). Bonferroni corrections were carried out. AUC 
(Area under the curve) was used to compare the metabolic variables in the liver and 
subcutaneous tissue. 
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Summary of results  
Paper I: 
Tissue gas tensions and tissue metabolites for detection of organ hypoperfusion and 
ischemia 
Lars Wælgaard, Berit Marie Dahl, Gunnvald Kvarstein and Tor Inge Tønnessen  
 
During continuous hemorrhage we observed an almost linear, inverse relation between 
decreasing cardiac index (CI) and increasing blood loss. There was a more pronounced 
decrease in blood flow to kidney and muscle than reduction of CI. Flow in hepatic artery 
decreased to about the same degree as CI while intestinal blood flow, measured as portal 
flow, fell relatively less compared to CI. From baseline to a CI of ~3500 ml/kg/m2 we 
observed only a moderate fall in mean arterial pressure (MAP), but thereafter a more rapid 
decline was noted. 
During reduced blood flow, but still aerobic conditions, PCO2 increased significantly (1-4 
kPa) in all the investigated organs There were no significant change for tissue metabolic 
parameters lactate, LP ratio, and glycerol .  
Until a reduction in CI to about 3000 mL/kg/m2 PO2 fell at a rate of 0.4-0.5 kPa/L decline of 
CI. After this a more pronounced decrease of 1.3-1.8 kPa/L was seen. The kidney reached 
zero PO2 significantly earlier than in the other organs. 
Below the critical CI levels LP ratio, lactate and glycerol increased significantly, while PCO2 
attained a much faster increase than during aerobic conditions. Thus, only PCO2  increased 
significantly both during aerobic and anaerobic conditions.   
In kidney and liver there were no significant differences in CIcrit for PCO2, lactate, pH and 
bicarbonate. In muscle and intestine we found a slightly lower CIcrit for lactate than for PCO2. 
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In all the investigated organs CIcrit values were lower for glycerol and LP ratio than for PCO2 
and lactate. There were no significant organ differences for glycerol and LP ratio. 
In the intestine the microdialysis catheters were placed intraluminally, and pyruvate and 
glucose were thus not detected until the mucosa had become leaky, and the barrier seriously 
disturbed (93;94). Under baseline conditions glucose is not detectable with microdialysis in 
the gut lumen (95). The basal intraluminal values for lactate and glycerol were almost 
identical to what other researchers have found (0,08 vs 0,11 mmol/l and 15.9 vs 16.2 μmol/l 
respectively) (96).  In the intestine we did not calculate the LP ratio as several values of 
pyruvate was below the detectable level. Glucose in liver and kidney increased during the first 
period of hemorrhage, but dropped sharply at the anaerobic threshold. Mean arterial 
hemoglobin stayed unchanged until about 60 % of total blood loss, and then it fell from about 
9.5 g/dL to 6 g/dL at the time of death.  
 
Paper II: 
Microdialysis for Monitoring Inflammation: Efficient Recovery of Cytokines and 
Anaphylotoxins Provided Optimal Catheter Pore Size and Fluid Velocity Conditions 
L. Wælgaard, A. Pharo, T. I. Tønnessen, and T. E. Mollnes. 
 
Microdialysis has become an established method to evaluate tissue metabolism, and in the 
clinic, measuring low molecular weight metabolites like glucose, lactate, pyruvate and 
glycerol can give valuable information to diagnose tissue ischemia by use of a 20 kDa 
molecular weight cut off membrane. 
With the introduction of a 100 kDa microdialysis catheter measurements of inflammmatory 
mediators have become possible. Because no systematic studies had been done on 
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determining the recovery of a broader panel of inflammatory mediators like cytokines and 
anaphylatoxins, we wanted to evaluate the microdialysis system for this purpose.  
In an in vitro study, we compared the use of 20 kDa and 100 kDa microdialysis catheters at 
three different velocities (0.3, 1.0 and 5.0 µl/min) in recovering relevant inflammation 
markers from reference preparations, namely the cytokines TNF-α, IL-1β, IL-6 and IL-10 
(17–28 kDa); and the chemokines IL-8, MCP-1, IP-10 and MIG (7–11 kDa); in addition to 
complement anaphylatoxins (C3a, C4a, C5a; 9–11 kDa). Recovery with the 100 kDa filter 
was as follows: IL-1β 75%, MCP-1 55%, MIG 50%, IL-8 38%, C4a 28%, IP-10 22%, C5a 
20%, C3a 16%, IL-6 11%, IL-10 8% and TNF-a 4%. The highest recovery for the 
chemokines and anaphylatoxins was consistently at velocity 1.0µl/min, whereas IL-1β and IL-
10 recovered most efficiently at 0.3 µl /min.  
 
Paper III: 
Microdialysis Monitoring of Liver Grafts by Metabolic Parameters, Cytokine 
Production, and Complement Activation 
Lars Wælgaard, Ebbe Billmann Thorgersen, Pål-Dag Line, Aksel Foss, Tom Eirik Mollnes 
and Tor Inge Tønnessen. 
We wanted to explore whether microdialysis with a 100 kDa cut off filter could be used to 
monitor ischemia, inflammation and rejection after liver transplantation. Catheters were 
inserted into both the left and right liver lobe. A reference catheter was introduced 
subcutaneously more than 5 cm away from the surgical wound. The catheters were left in 
place for a median of 156 hours (138.25-167.5). Metabolic parameters were analyzed bedside 
with the CMA 106 Analyzer at 1 hour intervals the first 24 hours and then every second hour 
for the next six days.  
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In patients with an uncomplicated postoperative course, lactate in the liver fell to normal 
values within 12 to 24 hours. Also in the subcutaneous tissue a decrease to low values was 
seen, but a higher steady-state value was measured in liver. The LP ratio also showed a rapid 
decrease to a steady level of about 10 in the liver, bur was significantly higher in the 
subcutaneous tissue. Glycerol was significantly higher in subcutaneous tissue than in liver. In 
patients undergoing an uneventful postoperative course, IL-6, IL-8 and C5a stayed low, but 
median IP-10 increased from 200 to 3000 pg/mL in the liver. 
Three of the four patients with biopsy verified rejections are described in detail in paper III 
(figures 3-5). 
Case 1 had a normal decrease in lactate reaching normal values within 24 hours 
postoperatively. On days 3 - 6 lactate increased in the liver and peaked at a value of 5 mM, 
while there was no increase in lactate in the SC catheter or in the blood. There was no 
increase in LP ratio or glycerol, ruling out ischemia as a cause of the high lactate. Pyruvate 
rose to the same extent as lactate, which is compatible with a hypermetabolic state. 
Complement C5a was measured to 8000 pg/mL immediately postoperatively, but decreased 
the next two days. Concomitantly with the rise in lactate, a pronounced increase of IP-10, IL-
8 and C5a in liver was found. There was no increase in ALT in blood until day 7 when a 
biopsy verified acute rejection. On day 7 high dose steroid was given as anti-rejection 
treatment and lactate, pyruvate, IP-10, IL-8 and C5a promptly declined to normal values 
strongly indicating that these parameters detected rejection 4 days earlier than rise in ALT, 
and anti-rejection treatment reestablished normal values. 
Case 2: Patient with fulminant hepatitis. This patient had a very complicated course as 
described in paper III. Four days after retransplantation C5a and IL-8 increased to 2500 and 
4000 pg/mL, respectively. Concurrently, IP-10 increased to 2200 on day 3. Histological 
examination verified rejection on day 9, four days after the catheters were removed.  
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Case 3: High values of both liver glycerol and liver enzymes that did not normalize 
postoperatively. IL-8 was elevated from the start of the postoperative course and fell 
gradually to values 2-3 times higher than those without major complications. At day 7 right 
hepatic artery showed reduced flow at the same time as LP ratio and glycerol suddenly 
peaked in the right lobe indicating ischemia. On day 13 the patient was rescheduled for 
surgery due to a choledochus stenosis. Prior to this, a new Doppler revealed marginal flow in 
the right hepatic artery, and a thrombus was removed at surgery. In the second postoperative 
course with microdialysis reestablished a rapid increase of IP-10 was observed reaching 
13000 picog/mL. A week later a histological examination verified acute rejection. 
The fourth patient with biopsy verified rejection showed normal metabolic values and low IP-
10 in the microdialysis catheters that was removed on day 5. Due to S-bilirubin elevation on 
day 5 and a suspected stenosis in ductus choledochus the patient was endoscopically treated 
with implantation of a biliary stent. Nevertheless, bilirubin continued to increase. A 
histological examination verified rejection on day 12.  
For all the transplanted patients median duration of the total ischemia time ((time from 
clamping of aorta to restituted flow in the portal vein) was 9.5 (8-11) hours. Median initial 
flow was 300 (233-429) ml in the hepatic artery and 1326 (1121-1925) ml in the portal vein.  
In the figure above AST, ALT and bilirubin in serum from the 20 patients in study III 
undergoing orthotopic liver transplantation (OLT) is shown. Median values were normalized 
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witin one week, but the variance is large showing that several patients had higher than normal 
values. Three of the patients had values of AST and ALT > 2000 U/L in the first 
postoperative days indicating a severe ischemia-reperfusion injury. 
Doppler ultrasound was performed in all the transplanted patients before the abdomen was 
closed, and then at least once daily. In three patients Doppler ultrasound revealed decreasing 
blood flow (resistive index > 0.9) and increasing lactate and LP ratio consistent with mild 
ischemia. (one of these patients is described as case 3). In the two other patients Doppler 
ultrasound revealed high flow resistance, and from day 1 to 2 they developed elevated LP 
ratios from 11 to 19 and 12 to 31, respectively. Later hepatic artery flow and the LP ratios 
rapidly normalized. 
Three other patients showed a high resistive index (RI) of 0.8-0.9 (normal values 0.6-0.75) 
which normalized to about 0.6 on the second or third day, without any elevation in the LP 
ratios.  
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Discussion  
Changes in regional and systemic blood flow during hemorrhagic shock 
We applied a continuous volume-controlled hemorrhagic shock model where blood was 
withdrawn continuously equivalent with 8 % of the total blood volume every hour. In a 
previous study we used a stepwise bleeding pattern (97). Continuous bleeding, rather than 
stepwise, is often encountered in patients with major occult bleeding from solid abdominal 
organs. We believe our model is highly relevant for such clinical situations. In most other 
studies shock has been achieved by rapid bleeding to a given blood pressure (23;98;99) by 
abruptly drawing a specific percentage of the blood volume (5;100)  or until the subjects get 
unstable (18). These studies have correspondingly not been able to define the exact onset of 
organ ischemia (anaerobic threshold). This is the first study on hemorrhagic shock with 
simultaneous measurements of circulatory and multiple parameters in such a large number of 
organs.  
With increasing hemorrhage we observed an inverse relation between hemorrhage and CI. 
Muscular blood flow declined significantly and more than systemic blood flow. Blood supply 
to the kidney declined earlier and reached zero flow earlier than in the other organs. Intestinal 
blood flow was relatively better preserved than CI while hepatic flow had a parallel decrease 
compared with CI. 
From a 40 to 50% reduction in CI, flow to the kidney was reduced from 50 to 90%. Another 
study similarly measured an abrupt reduction in renal flow at about 40% blood loss (101). 
Under non-anaesthetic conditions a renal vasodilatation may take place during early stages of 
hemorrhage, while in anesthetized animals vasoconstriction has been reported (7). Under 
physiological conditions the kidney uses 90 % of its energy on fluid and electrolyte regulation 
and tubular reabsorption. The blood and oxygen supply is thus much higher than what is 
needed for basal metabolism, and renal oxygen consumption increases and declines 
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proportionally with blood flow and oxygen supply. So despite the early and more pronounced 
drop in flow to the kidney, signs of anaerobiosis were not seen earlier, because VO2 in the 
kidney was reduced much more than in other organs before turning to anaerobic metabolism. 
Hepatic artery flow decreased to about the same degree as CI, but remained almost unchanged 
between 30 and 50 % hemorrhage. This is in agreement with the unique buffer response of the 
hepatic artery, where the hepatic artery can dilate when portal flow is restricted, and can 
increase its flow by more than 25 % (97).  
In our study intestinal blood flow, indirectly measured by flow in the portal vein, was 
significantly better preserved than CI (p<0,05) This is in agreement with what we found in a 
previous study (7). Again there seems to be a difference in vascular tonus in anesthetized and 
not anesthetized animals with higher splanchnic flow in anesthetized cases (7). However, 
even though intestinal blood flow was better preserved, signs of intestinal hypoxia appeared 
earlier than in the other tissues. Like previous studies we found indications of intestinal 
ischemia at blood flow levels 50-60% of baseline (102). 
The anatomically close proximity of the arterioles and venules in the intestinal mucosa and 
gradient between arterial and venous oxygen make O2 to shunt at the lower part of the villi. 
Thus, at the top of the villi PO2 is low rendering the villi very prone to ischemia. Due to 
shunting and low oxygen tension,  CO2 accumulate in the tip of mucosal villi. This counter-
current shunting of oxygen makes the intestinal mucosa more vulnerable to hypoxia following 
hypovolemia (103).  
Hemoglobin was stable until CI of about 2000 mL/kg/m2, and then it decreased from about 
9.5 to 6 at the time of death. Since no external fluid was administered to the animal, the 
decrease in hemoglobin is highly likely recruitment of interstitial fluid into the circulation as 
an attempt to counteract the development of shock due to blood loss.  
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Metabolism in hemorrhagic shock  
As PO2 approached zero in the four organ systems, we observed a rapid increase in lactate 
and LP ratio and a steep fall in pH and bicarbonate. At this point we also observed a marked 
fall in glucose and increase in glycerol and PCO2 (2-4 fold) in the four organ systems. Though 
lactate is most often regarded as a marker of ischemia, increasing tissue levels of lactate may 
also reflect hypermetabolism (104), inhibition of pyruvate dehydrogenase (105) and inhibition 
of mitochondrial respiration (106;107). The LP ratio is not changed in hypermetabolic 
conditions because a parallel increase in lactate and pyruvate keeps the LP ratio unchanged. 
In subcutaneous tissue adrenergic substances may stimulate phospholipase A to split the 
phospholipids into glycerol and fatty acids. During the immediate postoperative phase 
glycereol will therefore increase subcutaneously. This moderate rise does not indicate 
ischemia (108). High glycerol values measured in organs after transplantation, on the other 
hand, is most likely a sign of cell membrane disintegration and damage. 
During anaerobic conditions protons are released from lactic acid, hydrolysis of high energy 
phosphate compounds (ATP and ADP) and dissociation of phospholipids. A pronounced 
buffering of H+ ions by proteins and HCO3-, however, prevents a life threatening acidosis. As 
much as 30-50% of lactic acid is buffered by HCO3-. Consequently, lactate and PCO2 increase 
in parallel during ischemia (102). In this buffering process, PCO2 rises at the expense of 
HCO3-, so the total CO2 content is not changed. 
 
The role of PCO2 as a parameter of ischemia  
There is a large body of evidence from experimental studies with tonometric measurements in 
the stomach or in intestine supporting  the use of tissue PCO2 as a marker of ischemia of 
(21;109-112). It is well established that PCO2 detects regional hypoperfusion and flow 
stagnation (113). However, controversy exists whether PCO2 is a sensitive and specific 
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detector of anaerobic metabolism. Some authors consider tissue PCO2 a universal marker of 
tissue hypoxia (17;114), others argue that the increased tissue levels following ischemia 
reflects the reduced flow per see and not increased anaerobic production (115-119). This 
might look like a controversy, but all authors find that PCO2 increases with tissue hypoxia 
caused by ischemia. In rare cases of pronounced anemia or extreme systemic hypoxia tissue 
hypoxia may occur with less increase in PCO2 than if tissue ischemia is caused by ischemia. 
In these cases PCO2 is generated under ischemic conditions, but due to high compensatory 
blood flow CO2 is effectively removed from ischemic tissue, making the rise in PCO2 less 
pronounced. Some researchers have proposed that the anaerobic threshold can be defined as 
the point where the gradient between tissue and venous PCO2 starts to increase (118;119). 
The gradient between tissue and venous gas tensions started to rise concurrently with PO2 
approaching zero. Thus, the steep rise in tissue PCO2 seems to start when the anaerobic 
threshold is reached. 
The most important finding in our study is that PCO2 is a marker of hypoperfusion both under 
aerobic and anaerobic conditions. PCO2 increased significantly by 1-4 kPa also during initial 
hemorrhage when the tissues was still able to compensate the reduced blood supply by 
increasing their oxygen extraction and maintain aerobic metabolism. This is different from the 
other parameters investigated which did not change significantly under aerobic conditions. 
PCO2, however, heralded anaerobic metabolism simultaneously with lactate and L/P-ratio 
when measuring in kidney and liver, but earlier in intestine and skeletal muscle. It must be 
emphasized that despite significant differences in CIcri , the differences for various ischemia 
markers are small.  
In study I we found anaerobic metabolism in abdominal organs when arterial values for pH, 
bicarbonate, BE and lactate were still normal. Values of systemic parameters reached 
significance at lower CI-values (1900-2000 mL/kg/m2) than in abdominal organs. Thus, 
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anaerobic metabolism in abdominal organs may be present despite normal arterial levels of 
these variables.  
 
Recovery of substances across the microdialysis membrane 
Microdialysis is a reliable method for sampling small hydrophilic molecules. With long 
enough membrane, slow speed and small hydrophilic molecules like glucose, pyruvate and 
lactate, the recovery comes close to 100 % (120). The relative recovery is defined as the ratio 
between the concentration of the actual substance in the dialysate and in the tissue, and is 
expressed as percentages.  
For larger molecules like cytokines, the recoveries may be as low as a few percent even when 
the pore size of the dialysis membrane is 100 kDa (121).  
Several factors will influence the degree of recovery like analyte concentration, diffusion 
coefficient which includes physical and chemical properties of the molecule, the molecular 
quaternary structure and the degree of hydrophilicity and hydrophobicity. While small 
hydrophilic substances easily pass the dialysis filter, hydrophobic, large proteins may stick to 
the microdialysis membrane, clearly influencing the recovery. Finally, perfusion flow 
velocity, probe membrane properties, temperature and resistance to diffusion of the analytes 
will also influence the recovery within different types of tissues (121). 
Significantly more protein is recovered with the 100 kDa catheter (122). Helmy et al. (123) 
found that nine out of 12 cytokines showed improved relative recovery when a colloid 
(perfusion fluid supplemented with 3.5% human serum albumin) was used as the perfusate 
compared with a standard crystalloid fluid. Relative recovery for the two perfusion fluids was 
145% and 92 %, respectively. Addition of a colloid such as dextran or albumin to the 
perfusate (in our studies Plasmodex as recommended by the CMA) reduces the loss of fluid 
across the microdialysis membrane, which otherwise would lower the relative recovery.  
 51 
The concentration of inflammatory mediators is very low under physiological conditions, at 
nano- and even picogram levels. During inflammation, however, the levels may increase 10 to 
1000 fold so detecting changes will then be sufficient for monitoring.  
In vitro calibration can be done with mediums containing known concentrations. In clinical 
trials, however, it will not be possible to calibrate with known reference values (124), 
Investigators have compared in vitro and in vivo measurements with a similar microdialysis 
probes (125-128). In vivo recovery tends to be lower than the in vitro levels (129). Thus, one 
must regard the recovery numbers as semiquantitive. Systematic studies on recovery of 
inflammatory substances in vivo are lacking.  
In vivo, microdialysis IL-6 and IL-1β from human brain has shown to recover with 100 kDa 
pores (130). In a clinical comparison of catheters with 20kDa and 100 kDa molecular cut off 
small cerebral metabolites (lactate, pyruvate) recovered comparably well with a cut off of 100 
kDa and 20 kDa. The 100 kDa catheters can therefore be used for measurements of small and 
large molecules (122). 
 
Microdialysis as a diagnostic tool in liver transplantation 
In a feasibility study (paper III) we used microdialysis catheters in the liver and subcutaneous 
tissue to monitor patients the first seven days after liver transplantation. We were able to 
confirm that it is possible to recover both small metabolic and large inflammatory molecules 
from transplanted livers by the use of microdialysis catheters with 100 kDa MWCO.  
Regarding the metabolic parameters we found a rapid normalization of liver lactate and LP 
ratio in patients with an uneventful course in accordance with a previous study (89). The 
higher LP ratio in subcutaneous tissue reflected low values of lactate and even lower values of 
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pyruvate, and was not a sign of ischemic metabolism since there was no increase in lactate 
values.  
Stable, but somewhat higher levels of glucose was seen in the liver compared to subcutaneous 
tissue. In the experimental shock study, we observed higher baseline values for glucose in the 
liver, which increased with progressive blood loss. However, when blood loss exceeded the 
anaerobic threshold glucose rapidly decreased. Increased liver glucose during ischemia has 
been reported previously and can be explained by increased glycogen degradation (131).  
In uncomplicated patients glycerol was found to be higher subcutaneously than in the liver. 
Increased adrenergic stimulation due to the surgical and postoperative stress, split 
triglycerides to fatty acids and glycerol, and may explain the higher subcutaneous values 
postoperatively.  
After pilot studies we regarded IL-6, IL-8, MCP-1 and IP-10 and the complement split 
product C5a as relevant and recoverable inflammatory mediators. These were analyzed on day 
1, 3, 5 and 7. Due to limited resources, C5a was only analyzed in two patients with 
complications and two patients without complications.  
We found a rise in IL-6 immediately after transplantation, normalizing at day 3. This finding 
is in accordance with previous findings and may represent a minor local inflammatory 
reaction to insertion of the catheter. In uncomplicated patients low and stable IL-8 and MCP-1 
values were detected.  
In ”normal” patients we found, somewhat surprisingly, a steady increase of IP-10 median 
values in the liver (ranging from about 200 picog/ml to 3000 picog/ml with large variance), 
but not in subcutaneous tissue. It may reflect a liver normal regeneration process or a 
subclinical ”mini-rejection”, involving parts of the inflammatory network of which IP-10 is a 
marker. “Normal” patients were defined as patients without major clinical complications 
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during the time the catheters were inserted. This did not exclude that some of patients had 
subclinical rejection with somewhat increased liver enzymes or bilirubin not high enough to 
justify a liver biopsy. Our main hypothesis was therefore that increased IP-10 in normal 
patients most probably reflected subclinical mini-rejections. This is in accordance with the 
observation that with clinical biopsy verified rejection, IP-10 was 10 – 50 fold higher than in 
the normal population and that an increase in IP-10 probably reflects rejections at different 
degrees. 
Recently, our group finished a larger study of 70 liver transplanted patients and a total of 73 
transplantations (132;133). A longer registration time was conducted with microdialysis 
measurements for 9 (0-26) days. Thirteen patients had histologically verified rejections and 
nine patients developed hepatic artery occlusion. Forty patients were without major 
complications, and inflammatory parameters were measured for the 17 patients with least 
fluctuations in s-bilirubin and s-ALT. In line with our measurements in study III, IP-10 stayed 
at low values in “uncomplicated” patients, but increased up to 20 times in patients with a 
histologically verified rejection. Interestingly, patients with ischemia due to HAT showed low 
IP-10 levels as the uncomplicated patients. So IP-10 stands out as a promising and specific 
parameter of rejection. 
After reperfusion, lactate rapidly normalized. A late increase in lactate may represent 
ischemia or increased metabolism, as described above. In ischemic tissue the LP ratio will rise 
because of the rise in lactate and the drop in pyruvate. In two ”normal” patients we saw a 
transient increase in lactate and the LP ratio which paralleled decreased flow and higher 
resistive index in hepatic artery.  
Case 3  with HAT, developed a rapid rise in lactate and a rise in L/P ratio to 60, confirming an 
ongoing ischemia. In the larger clinical follow-up study (see above) a much higher rise in 
lactate was seen in patients with HAT than rejection, indicating that lactate and pyruvate 
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stands out as the most useful parameters of ischemia. Importantly it provides a continuous 
monitoring, as opposed to the cytokine measurements for which we have no ”fast-track” 
analyzer system. 
Patients with rejection had a rise in intrahepatic lactate and pyruvate indicating a 
hypermetabolic state. A marked increase in inflammatory mediators was found,  suggested a 
rejection, which later was histologically verified by a biopsy. The hypermetabolic state is 
most likely caused by T-cells and other cells from the immune system that with activation 
increases the metabolism several fold. Despite oxygen being present, the increased aerobic 
glycolysis induces a spill-over of lactate and pyruvate with increased values of both. Thus 
LP-ratio does not increase as opposed to events of ischemia.  
Case 1 and 2 developed graft rejection.  They demonstrated high values of C5a, but normal 
IL-8 immediately after the transplantation. C5a normalized transiently, but increased later in 
parallel to IL-8 several days before the rise of s-ALT and s-bilirubin suggesting  liver damage. 
In studies by Silva et al (84;134) high levels of lactate and intrahepatic complement activation 
were both predictive of increased IRI and initial poor graft function. All the three cases 
suffering from rejection showed a 10 to 50 fold rise of IL-8. However, IL-8 does not seem to 
be specific for rejection. In the large follow-up study, referred to above (132;133) , IL-8 was 
more elevated after HAT than after rejection. In another study IL-8 was found to be higher 
after infection than after rejection (135). To make a diagnosis IL-8 needs to be compared to 
other parameters and is therefore less specific for rejection than IP-10. 
For patients undergoing a liver transplantation microdialysis may provide early valuable 
information during the first postoperative week to diagnose ischemia or rejection. This can be 
of great practical help especially after HAT and acute rejection when early intervention is 
needed.  
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Conclusions:  
 
Hemorrhagic shock model 
 Organ blood flow reduction, caused by bleeding, varies widely between different 
organs with the kidney being the first to attain zero blood flow, while the intestine has 
the highest macrovascular flow  
 PtCO2 increases 1 – 4 kPa at a rate of 0,30 – 0,72 kPa/hour with decreasing blood 
supply even when the metabolism is aerobic in contrast to metabolic parameters of 
ischemia that does not change significantly  
 PtCO2 increases rapidly with the onset of anaerobic metabolism in all studied organs 
with anaerobic threshold values of median 7.7 – 9.3 kPa and a rate of increase of 3.7 – 
9.7 kPa/hour i. e. more than tenfold the rate compared to aerobic conditions  
 Under anaerobic conditions both PtCO2, tissue lactate, LP ratio and tissue glycerol 
increase profoundly, while tissue pH and bicarbonate decrease strongly, indicating 
CO2 generation caused by tissue metabolic acidosis buffered by bicarbonate  
 PtCO2 can be used as a marker of tissue hypoperfusion under both aerobic and 
anaerobic conditions. It gives an earlier warning of hypoperfusion than metabolic 
markers, and increases concomitantly with or earlier than other markers at the onset of 
tissue anaerobiosis 
In vitro microdialysis study 
 20 kDa microdialysis catheters had zero recovery of a panel of cytokines, chemokines 
and complement factors, despite the fact that nearly all the tested substances had 
molecular weight less than 20 kDa 
 100 kDa catheters recovered all the immunological substances, but at very different 
degrees 
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 Maximum recovery was for most substances at a rate of 1 µL/min and we therefore 
decided to use this rate in the clinical study 
Clinical microdialysis study on liver transplanted patients 
 Metabolic parameters (glucose, lactate, pyruvate, glycerol) and immunological 
parameters (IL-6, IL-8, MCP-1, IP-10) and complement factor C5a was recovered in 
100 kDa microdialysis catheters during 7 days postoperatively.  
 In patients without complications lactate in the liver decreased rapidly and attained 
normal values within 24 hours. For the next six days values were relatively stable. 
 Lactate in the liver was higher than lactate subcutaneously 
 LP ratio and glycerol was higher in the subcutaneous tissue than in the liver 
 IL-6 was higher subcutaneously than in the liver the first postoperative days, but was 
not different from liver values from days 3 
 IP-10 increased in the liver, but not subcutaneously during the observation period 
 In a patient with rejection there was a substantial increase in lactate, pyruvate, IP-10, 
IL-8 and C5a four days before increase in ALT and four days before rejection was 
biopsy verified. Anti-rejection treatment with high dose methylprednisolone was 
started and all measured parameters rapidly declined 
 In a patient with hepatic artery thrombosis, a rapid rise in lactate and glycerol was 
demonstrated 
 
Further perspectives 
We have outlined the theoretical mechanisms and showed in an experimental animal study 
that PCO2 has a great potential in monitoring hypoperfusion both under aerobic and anaerobic 
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conditions. A PCO2 sensor with real-time read-out has been developed by our group for tissue 
measurements and approved for human use. In experimental animal studies the sensor was 
able to detect ischemia in heart, liver, intestine, kidney and skeletal muscle within 1 – 5 
minutes. This may become a valuable tool for the clinician in early detection and treatment of 
organ ischemia. 
Our research group has carried out a study on 70 liver transplant patients after the completion 
of study III in this thesis. In 73 transplanted livers, there were 20 rejection when catheters 
were implanted (up to 28 days, median 9 days), and 9 patients with ischemia. Ischemia was 
detected by 100% sensitivity and specificity, and rejection with > 84% sensitivity and > 90% 
specificity. These results were achieved by measuring lactate and pyruvate bedside by 
sampling every 1 – 2 hour. Ischemia was detected close to real time, and rejection was 
detected 2 – 5 days before increase in ALT or bilirubin. No complications related to the 
catheters were detected. We have now extended this study in children by also placing a 100 
kDa catheter in the abdominal cavity between intestinal loops. In this way we have detected 
portal vein thrombosis (venous ischemia in intestine), intestinal perforation and peritonitis. 
We have also in pilot patients inserted microdialysis catheters percutaneously into the 
peritoneal cavity between intestinal loops under ultrasound guidance. This has been in 
patients at risk of abdominal compartment syndrome and in septic patients on high doses of 
pressors. In one patient with high doses of norepinephrine we detected intestinal ischemia. By 
decreasing the dose, accepting a lower MAP and adding dobutamine, the intestinal ischemia 
was reversed. We are currently planning studies to use abdominal microdialysis to guide fluid 
and vasoactive treatment in patients with shock (hypovolemic, cardiac, septic) to prevent 
intestinal ischemia. Also a study where we aim to detect postoperative infections after 
abdominal surgery earlier than with current monitoring is planned. In this study we will place 
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catheters near intestinal anastomosis, and in the surgical wound. We have in animal studies 
(cecal ligation model) found that this approach detect infection very early. 
The current thesis has been hypothesis generating for later performed and planned studies. It 
is our hope that this will benefit our patients implying reduced suffering and better outcome. 
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Background: The aim of this study was to evaluate how tissue gas tensions and tissue 
metabolites measured in situ can detect hypoperfusion and differentiate between aerobic and 
anaerobic conditions during hemorrhagic shock. We hypothesized that tissue PCO2 (PtCO2) 
would detect hypoperfusion also under aerobic conditions, and detect anaerobic metabolism 
concomitantly with, or earlier than other markers.  
Methods: Prospective experimental animal study with eight anesthetized pigs subjected to a 
continuous blood loss ~8 % of total blood volume per hour until death. We measured cardiac 
index (CI), organ blood flows, and tissue levels of PO2, PCO2, glucose, pyruvate, lactate and 
glycerol in intestine, liver, kidney and skeletal muscle.  
Results: With reduction in blood flow to the organs under aerobic conditions, PtCO2 increased 
~1 - 4 kPa from baseline. With the onset of tissue hypoxia there was a pronounced increase of 
PtCO2, lactate, lactate-pyruvate (LP) ratio and glycerol. Tissue pH and bicarbonate decreased 
significantly, indicating that metabolic acid was buffered by bicarbonate to generate CO2. 
Conclusion: Moderate tissue hypoperfusion under aerobic conditions is associated with 
increased PtCO2, in contrast to metabolic parameters of ischemia (lactate, LP ratio, glycerol) 
which remain low. From the onset of ischemia there is a much more rapid and pronounced 
increase in PtCO2, lactate and LP ratio. PtCO2 can be used as a marker of hypoperfusion under 
both aerobic and anaerobic conditions; it gives an earlier warning of hypoperfusion than 
metabolic markers, and increases concomitantly with or earlier than other markers at the onset of 
tissue anaerobiosis.  
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Severe bleeding due to major trauma or surgery is a serious condition with mortality rates as high 
as 30 %.1 Optimal resuscitation is difficult to achieve since systemic parameters like blood 
pressure and heart rate do not reliably reflect blood flow to internal organs.2-5 Visceral organs like 
the liver, intestine and the kidney may for instance be hypoperfused while systemic variables are 
still close to normal.6-9 Several authors have therefore advocated measuring ischemia markers in 
the organs to detect if O2 supply is sufficient to support the O2 demand.10-12  
Tissue PCO2 (PtCO2) as a marker of hypoperfusion is supported by previous studies.13-20 
Gastric tonometry has been shown to detect gastric hypoperfusion during shock.3;4;11;21 
Microdialysis is a clinically available technology that can be used in muscle and abdominal 
organs like the liver and intestine to detect ischemia. 22-26 There are also emerging clinical 
technologies for real-time measurement of PCO2 in muscle and internal organs.27-29 The majority 
of PCO2 studies have been carried out in different parts of the GI tract, mainly stomach, and less 
is known about PCO2 in solid organs during hemorrhagic shock.18;20;30;31 No studies have 
compared real-time PtCO2 in several organs with other simultaneously measured microdialysis 
tissue markers of ischemia like lactate, lactate-pyruvate ratio (LP ratio) and glycerol. In this 
exploratory study we used a model of continuous hemorrhage with measurements of organ blood 
flow as well as tissue PCO2, PO2, pH, lactate, pyruvate, glucose and glycerol in skeletal muscle, 
kidney, liver and intestine.  
The aim of this study was to evaluate how tissue gas tensions and tissue metabolites 
measured in situ as well as systemic parameters can detect hypoperfusion and differentiate 
between aerobic and anaerobic conditions during hemorrhagic shock. We hypothesized that 
PtCO2 could detect hypoperfusion also under aerobic conditions, and detect anaerobic 
metabolism concomitantly with, or earlier than other markers depending on the organ studied. 
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Materials and methods 
The study protocol was approved by the Institutional Committee of Animal Care and Use 
and performed according to international guidelines 32. Eight male Norroc pigs with a median 
weight of 60 kg (range 53-71 kg) were included.  
The animals were kept fasting overnight with free access to water and were sedated with 
i.m. ketamine (20 mg/kg), azoperon (3mg/kg) and atropin (0.02 mg/kg). Anesthesia was induced 
by i.v. penthobarbital (4 - 5mg/kg) and morphine (0.2 mg/kg) and maintained with isoflurane 
inhalation 1.0-1.5 % and infusion of morphine (0.15-0.2 mg/kg/h).  
 
Surgery 
A tracheostomy was performed and mechanical ventilation established at 7 – 10 L/min at a 
respiratory rate of 14 per min and tidal volumes of 0.5 – 0.7 L aiming at normocapnia (~5.3 kPa). 
(Kion™, Siemens AB, Solna, Sweden). Inspired oxygen fractions (FiO2) were between 0.25 – 
0.35 to attain normoxia (pO2 >12 kPa).  PEEP was zero. A three luminal catheter was introduced 
in the carotid artery for continuous arterial blood pressure recording, blood sampling and 
controlled bleeding. A multilumen, fiberoptical pulmonary artery catheter (CCombo™, Edwards 
Lifesciences LLC, Irvine,CA) was inserted to record cardiac index, SvO2, and core temperature. 
Cardiac index was determined by continuous thermodilution which has a delay of 9 – 11 minutes 
until the results appear. In our graphs we have compensated for this time delay.  
Through a midline laparotomy dissection of the portal vein, hepatic artery, descending 
aorta and inferior caval vein was performed and catheters were introduced in the portal vein, 
hepatic vein and inferior caval vein for extraction of blood samples. Transit time ultrasound flow-
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probes (Medistim AS, Oslo, Norway) were placed around the portal vein, the hepatic artery and 
the descending aorta, immediately proximal to the bifurcation of the iliac arteries. 
Through a flank incision from iliac crest to 12th rib and after dissection of the kidney we 
introduced a short catheter (Venflon™, Viggo 1.0 mm Ø) into the left renal vein and a transit time 
ultrasound flow probe around the renal artery. 
The following measurement devices were used: Neurotrend™ Multiparameter Sensor tissue 
monitoring system (Diametrics, Inc. 2658 Patton Rd. Roseville, MN 55113, USA) was inserted 
into the tissue of the liver and the left kidney to measure PtCO2, tissue PO2 (PtO2) and tissue pH. 
Via an antimesenteric incision of the small intestine two Severinghaus type PCO2-electrodes (MI 
720™, Microelectrodes, Bedford, NH) were placed in the lumen. Skeletal muscle PCO2 was 
measured in the gluteal muscle. Intestinal lumen and skeletal muscle PO2 was monitored by an 
oxygen electrode (Licox™, Integra, Plainsboro, NJ, USA). Microdialysis catheters (CMA 60 MD 
Catheter, CMA Microdialysis AB, Solna, Sweden) were inserted into the gluteal muscle, kidney, 
liver and the intestinal lumen.  
To compensate for current fluid loss Ringer’s Acetate 10ml/kg/h was administered during 
surgery. Core temperature was kept at 38ºC±1 using a temperature regulating blanket. An 
infusion of glucose 10 % was given to maintain blood glucose 4 – 8 mM throughout the 
experiment. 
 
Protocol for hemorrhagic shock 
In pilot experiments we tested animals (n > 10) that underwent major abdominal surgery with 
equivalent anesthesia and with insertion of intraorgan measurements of the same parameters as 
used in this study, but no bleeding protocol was started. These animals were observed for 12 
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hours after surgery, and showed no change in cardiovascular parameters, or in any of the 
parameters used for systemic or intraorgan detection of ischemia. The drift of the measurement 
devices were minimal. Based on this, we decided both for ethical and economic reasons that a 
control group was not deemed necessary in this study, and each animal could serve as its own 
control. 
 After the end of surgery the animals were allowed to stabilize for one hour. During this 
hour three samples of baseline values of all parameters confirmed no changes in baseline values 
showing that the pigs were stable after surgery. The protocol started with another two sets of 
baseline values during ten minutes. With a volume pump (IVAC™ 598, Cardinal Health Inc., 
Ohio, USA) we performed a continuous withdrawal of blood from the carotid artery catheter 
corresponding to ~8% of the total blood volume every hour. Blood volume was calculated as 65 
mL/kg body weight.33 There was no infusion of crystalloids or colloids while the withdrawal of 
blood was ongoing until death. 
 
Data Collection 
PtCO2, PtO2, tissue pH, tissue HCO3- and temperature from the Neurotrend, PtCO2 from the 
Severinghaus-type sensors and PtO2 from the Licox™ probes were recorded every 60 seconds. 
Every 30 minutes, microdialysates were collected and analyzed by a CMA 600 Microdialysis 
Analyzer for tissue levels of lactate, pyruvate, glycerol and glucose. Blood samples were 
simultaneously drawn from the carotid artery, renal vein, hepatic vein, portal vein and inferior 
caval vein and analyzed immediately (Radiometer ABL 625, Copenhagen, Denmark). 
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Calculations and statistics 
To determine transition to anaerobic metabolism we aimed at defining the cardiac index value 
(critical cardiac index, CIcrit) when the rapid rise in lactate, LP ratio, PtCO2 and glycerol 
commences, and tissue pH, bicarbonate and glucose declines. This corresponds to the maximal 
curvature of the graph, which can be determined by dual line regression analyses.34 Thus, we 
carried out dual line regression analyses with cardiac index on the x-axis and each variable on 
every animal in the organs studied on the y-axis. Critical CI was defined as the point of 
intersection for the two linear regression lines with the lowest sum of squared residuals.34 This 
rapid increase or decrease in parameters reflecting anaerobic metabolism occurs near the 
transition to anaerobic metabolism, and we therefore propose that CIcrit can be used as parameter 
for commencement of tissue hypoxia. Each variable is presented as median with interquartile 
range (25% - 75%). To test for significant differences between the critical CI values, we applied 
Kruskal-Wallis One Way Analysis of Variance on Ranks, and the post-hoc Student-Neuman 
Keuls (SNK) test for a multiple comparison of all the groups.    
We also calculated the time derivates, dPCO2/dT(time) and d[lactate]/dT, under aerobic 
and anaerobic conditions for the investigated organs. This gives information on the rate of 
increase of these parameters. The rapid increase in time derivate commenced at the critical CI 
value, adding to the argument that CIcrit reflects the anaerobic threshold. 
Areas under the flow curves (AUC) (Fig. 2) were calculated using the sum of rectangles 
method. To test if there were significant differences between the AUC of blood flow in different 
organs, we applied Kruskal-Wallis One Way Analysis of Variance on Ranks, and the post-hoc 
Student-Neuman Keuls (SNK) test for a multiple comparison of all the groups. 
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In one animal the renal venous catheter and in another the renal microdialysis catheter 
was obliterated. In two animals the intestinal microdialysis catheter failed. LP ratio was not 
calculated for the intestine due to some values of pyruvate being lower than the detection limit. 
 
Results   
Cardiac index (CI) decreased with increasing blood loss and showed a strong inverse linear 
correlation (r > -0.95 in each pig). Heart rate increased at CI of 4000 mL/kg/m2 reaching maximal 
rate at ~3000 mL/kg/m2 (Fig. 1A). From baseline to ~3000 mL/kg/m2 MAP decreased ~5 mmHg 
per liter decrease in CI. Thereafter MAP had a steeper decline at ~15 mmHg/L decay in CI (Fig. 
1B). CI is in Fig. 2 compared with organ blood flows expressed as percentage decrease from 
baseline. Blood flow to the kidney (p < 0.01) and skeletal muscle (p<0.01) was relatively more 
reduced than cardiac output, while intestinal (portal) blood flow was better preserved (p< 0.05). 
Hepatic artery blood flow decreased to the same degree as CI.   
PtO2 declined in all studied organs in the CI range from baseline to ~3000mL/min/m2 
(Fig. 3) at a rate of ~0.4 – 0.5 kPa/L decrease in CI. With further blood loss PtO2 decline was 
more pronounced (~1.3 – 1.8 kPa/L) until it reached zero. Zero PO2 was attained significantly 
earlier in the kidney than in the other organs (p < 0.02).  
Under aerobic conditions tissue LP ratio, glycerol and lactate remained low in all organs 
(Fig. 3 and 4, Table 2), but increased significantly and at a much higher rate below critical CI 
levels (CIcrit) (Table 1 and 2, Fig. 3 and 4).   
Only PtCO2 increased significantly under both aerobic and anaerobic conditions (Fig 4, 
Table 1 and 2). In all organs and for all variables the rate of increase was significantly and several 
fold higher under anaerobic compared to aerobic conditions (Fig. 3, Fig 4 and Table 2).  
 9 
In all organs CIcrit for LP ratio were significantly lower than for PCO2 and lactate (Table 
1). Glycerol increased at a significantly lower CIcrit (p < .01) than LP ratio in all organs tested. 
CIcrit for glycerol and LP ratio did not significantly differ between the organs. However, for 
lactate it was significantly lower (p < .05) in muscle compared to the other organs. There was no 
significant difference in critical CI values between PCO2, lactate, pH and bicarbonate in kidney 
and liver. In muscle and intestine CIcrit for lactate was significantly lower than for PCO2. Arterial 
lactate reached pathological values (> 2 mM) at CI ~2050 mL/kg/m2, whereas arterial pH, 
bicarbonate and BE reached values significantly lower than baseline at CI ~1900 mL/kg/m2. 
 
Discussion  
We found that i) organ blood flow reduction, caused by bleeding, varies widely between different 
organs with the kidney being the first to attain zero blood flow, while the intestine has the highest 
macrovascular flow; ii) PtCO2 increases 1 – 4 kPa at a rate of 0,30 – 0,72 kPa/hour (Table 1 and 
2) with decreasing blood supply even when the metabolism is aerobic in contrast to metabolic 
parameters of ischemia that does not change significantly; iii) PtCO2 increases rapidly with the 
onset of anaerobic metabolism in all studied organs with anaerobic threshold values of median 
7.7 – 9.3 kPa and a rate of increase of 3.7 – 9.7 kPa/hour i. e. more than tenfold the rate compared 
to aerobic conditions; iii) Under anaerobic conditions both PtCO2, tissue lactate, LP ratio and 
tissue glycerol increase profoundly, while tissue pH and bicarbonate decrease strongly, indicating 
CO2 generation caused by tissue metabolic acidosis buffered by bicarbonate.  
 
 
 
 10 
Phases during hemorrhagic shock 
With decreasing cardiac index due to increasing blood loss we found that organ metabolism 
progressed through two phases:  
Phase 1 starts at baseline and ends at the critical CI level (CIcrit). The metabolism is solely 
aerobic, and the phase is characterized by a progressive decrease in PtO2 9;31;35-37 and an increase 
in PtCO2, but no significant changes in tissue lactate, LP ratio, tissue glycerol or glucose in any 
organ or systemic blood (Fig. 3 - 4, Table 1 – 2).  
As blood flow declines, more oxygen is extracted from hemoglobin to keep a constant 
oxygen utilization (VO2) and CO2 generation (VCO2) in the tissue. With decreased blood flow 
more CO2 is consequently added to each volume unit of blood, and PCO2 will increase in venous 
effluent blood as well as in the tissue 36;38;39. Thus, the increase in PtCO2 under aerobic conditions 
is reflecting decreased blood flow (hypoperfusion/stagnation), and not increased aerobic VCO2.  
Phase 2 starts at the transition from solely aerobic metabolism to mixed aerobic and 
anaerobic metabolism and continues until the subject dies. As CI decreases below the anaerobic 
threshold a higher percentage of the metabolism becomes anaerobic, and when PtO2 is zero 
(anoxia) the metabolism has become purely anaerobic. The phase is characterized by marked 
increases in the tissue levels of PCO2, lactate, LP ratio and glycerol, and considerable decreases 
in tissue pH, bicarbonate and glucose. 
Under anaerobic conditions protons are released from lactic acid, ATP hydrolysis, and 
dissociated phospholipids 15. Protons are buffered by HCO3- to generate CO2 37;40. In accordance 
with this, not only pH, but also bicarbonate decreased markedly demonstrating a tissue metabolic 
acidosis (Fig. 4, Table 1). We found a high correlation between lactate and PtCO2 in ischemic 
tissue (below CIcrit) in accordance with previous findings under no-flow conditions 15;18;41 
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compatible with lactic acid being buffered by bicarbonate. The amount of CO2 generated (VCO2) 
under anoxic conditions is less than under aerobic conditions 3;40;42-45, but since CO2 is trapped in 
the tissue with minor blood supply, tissue PCO2 increase several fold despite lower VCO2. 
 
Determination of transition to anaerobic metabolism 
Lactate-pyruvate ratio is a robust marker of anaerobic metabolism as this ratio reflects the 
redox state of the cell (NADH x H+/NAD+ = (Lactate/Pyruvate) x KLDH)) and shows that 
pyruvate is being utilized to produce lactate; a sign of anaerobic glycolysis.46 Interestingly, 
increasing LP ratio was found at significantly lower CIcrit in all studied organs than lactate and 
PtCO2 (Table 1). This was because pyruvate initially increased when lactate increased, but 
pyruvate then decreased a lower CI. Since LP ratio, lactate and PtCO2 increase at different CIcrit, 
which of these parameters reflects transition to anaerobic metabolism? In liver and kidney the 
CIcrit for tissue PCO2, lactate, pH and bicarbonate are nearly equivalent which strongly indicates 
that these markers reflect the imminent ischemia (Table 1), LP ratio increases at CIcrit only 300 
mL/kg/m2 lower. Rather than speculating on which variable that most truly reflects an anaerobic 
threshold, we emphasize that despite CIcrit being significantly different for various markers the 
difference in values are rather small (Table 1) indicating that they reflect the same biological 
phenomenon. From a clinical point of view it would be logical to increase resuscitative efforts to 
prevent ischemia when the first marker (PtCO2) starts to increase and not waiting until LP ratio 
also increases.  
Only glycerol, which is a breakdown product of cell membrane lipids indicating severe 
cell injury or cell death, increases at a lower CIcrit than LP ratio. This is in accordance with the 
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notion that ischemia may last for some time before cell damage occurs, leaving time for initiation 
of therapy based on early ischemia markers like PtCO2 at a time when the cells are salvageable.  
 
Organ blood flow and tissue ischemia  
Splanchnic blood flow has been considered particularly vulnerable to hypovolemia. In our study, 
however, blood flow to the liver and intestine was surprisingly well preserved with increasing 
blood loss. When blood flow to the kidney was zero, blood flow to the intestine was not reduced 
by more than 50% (Fig. 2). However, in the kidney transition to anaerobic metabolism did not 
take place until blood flow almost reached zero, whereas signs of intestinal anaerobic metabolism 
were found at 50% of baseline blood flow (Fig. 2 – 4). These findings illustrate clearly that 
macrovascular flow at organ level does not reliably reflect microvascular blood flow and the 
transition to anaerobic metabolism5, and is as such of very limited value to differentiate serious 
blood loss from non-threatening blood loss. In that perspective intraorgan monitoring of tissue 
metabolites and gas tensions is preferred. 
 
Are systemic parameters sensitive enough to detect organ ischemia? 
The first signs of tissue ischemia occurred at SvO2 ~40, indicating that for hypovolemic shock a 
resuscitation target of SvO2 50 % would suffice. Arterial pH, bicarbonate, BE and lactate reached 
values significantly different from baseline at CI ~1900 – 2000 mL/kg/m2 which is significantly 
lower than the CIcrit we detected by tissue monitoring (Table 1 and Fig. 3 - 4). Thus, anaerobic 
metabolism in abdominal organs may be present despite normal arterial levels of these variables. 
The animals became tachycardic in the aerobic phase, and reached maximum heart rate 
when the organs became ischemic (Fig. 1). With a MAP > 50 mmHg there were no signs of 
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tissue ischemia, supporting clinical practice in resuscitation targeting MAP ~60 mmHg. 
However, if the patient has arteriosclerotic disease in the aorta or vessels supplying abdominal 
organs, or maldistributive shock, organ ischemia may occur at MAP 50 - 60 mmHg supporting 
the need for intraorgan monitoring.   
 
Putative clinical implications of this study 
Microdialysis catheters are clinically approved for monitoring liver22;26, intestine and skeletal 
muscle, and a PCO2 sensor 24-26 is FDA approved and CE marked for clinical use. We have 
carried out studies on liver transplant patients where we have inserted microdialysis catheters in 
transplanted livers and detected ischemia due to vessel thrombosis close to real time enabling 
reoperation at a time before irreversible injury occurred.26 Intestinal ischemia is detected by these 
devices when they are placed between intestinal loops, eliminating need to penetrate the intestinal 
wall. 25 Placement of the intraabdominal sensors can then be carried out through a paracentesis 
needle in less than 5 min. Thus, it is feasible to perform clinical studies with these devices in 
patients at risk of hemorrhagic shock both for measurements in skeletal muscle and abdominal 
cavity. PCO2 in skeletal muscle closely correlated with PCO2 in abdominal organs. Muscular 
PCO2 could therefore serve as a surrogate marker for these organs. In addition to early detection 
of ischemia, these devices can be used to guide therapy, as resuscitation to a cardiac index above 
CIcrit would rapidly normalize intraorgan parameters. This could be of particular benefit for 
patients with stenotic abdominal vessels, and for patients being treated with vasopressors like 
noradrenalin47 and vasopressin48 that may decrease microcirculation in abdominal organs despite 
elevation of MAP in shock.  
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Limitations 
The study is carried out on healthy anesthetized animals. Therefore the data cannot be 
extrapolated to awake individuals or patients with severe atherosclerosis, but most patients being 
treated for severe blood loss are heavily sedated or anesthetized, so our study design may be 
realistic from a clinical perspective.  
For measurements of gas tensions, we have used Neurotrend in kidney and liver, and 
Severinghaus type sensors for PCO2 in muscle and intestine, and a Clark-type sensor for PO2 in 
the latter organs. Thus, comparing tensions in intestine and muscle with liver and kidney could 
induce erroneous conclusions if the accuracy of the different methods were not comparable. To 
avoid this, we meticulously calibrated all devices before and after the experiment against known 
values of PCO2 and PO2 and developed algorithms for drift correction if needed. We therefore 
feel confident that despite using different devices our findings and conclusions are valid. 
 
Conclusion 
PtCO2 can be used as a marker of tissue hypoperfusion under both aerobic and anaerobic 
conditions. It gives an earlier warning of hypoperfusion than metabolic markers, and increases 
concomitantly with or earlier than other markers at the onset of tissue anaerobiosis. 
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Legend to figures 
 
Figure 1 
Cardiac index vs. heart rate, mean arterial pressure and mixed venous oxygen saturation 
during progressive blood loss. Values are medians with interquartile ranges.  
 
Figure 2 
Cardiac index (CI) vs. blood flow during progressive blood loss. Blood flows are shown 
as percentage change from baseline values. The grey dashed line represents median percentage 
reduction in cardiac index. Values are medians with interquartile ranges. 
 
Figure 3 
Tissue PO2 and tissue values of glycerol, glucose and the calculated lactate-to-pyruvate 
ratio (LP-ratio) vs. cardiac index (CI). Values are medians with interquartile ranges. When error 
bars are not visible, the interquartile ranges are less than the size of the symbol. 
 
Figure 4 
Tissue values of PCO2, lactate, pH and bicarbonate vs. cardiac index (CI). Values are 
medians with interquartile ranges. When error bars are not visible, the interquartile ranges are 
less than the size of the symbol. Lactate-pyruvate ratio for intestine is not depicted due to some 
values of pyruvate being less than detectable by CMA 600. 
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0,
 2
74
0)
 
8.
9 
 
(8
.2
, 9
.6
) 
L
ac
ta
te
 (m
M
) 
20
02
 #
 
(1
90
2,
 2
04
2)
 
2.
1 
 
(1
.9
, 2
.2
) 
22
90
  
(2
05
0,
 2
53
0)
 
1.
4 
 
(1
.2
, 1
.5
) 
23
03
  
(2
17
5,
 2
43
7)
 
1.
2 
 
(1
.1
,1
.4
) 
23
07
  
(1
98
0,
 2
62
2)
 
0.
2 
 
(0
.2
,0
,2
) 
L
P 
ra
tio
 
15
72
 §
 
(1
49
6,
 1
74
9)
 
13
.5
  
(1
2.
9,
 1
6.
2)
 
19
88
 §
 
(1
88
3,
 2
00
3)
 
22
.8
  
(1
9.
2,
 2
4.
9)
 
19
91
 §
 
(1
90
2,
 2
05
2)
 
20
.6
  
(1
9.
3,
 2
4.
0)
 
N
A
 
N
A
 
G
ly
ce
ro
l (
µM
) 
13
84
 §
§ 
(1
26
8,
 1
42
1)
 
16
  
(8
, 2
3)
 
15
72
 §
§ 
(1
49
4,
 1
73
4)
 
17
  
(1
5,
 3
1)
 
16
48
 §
§ 
(1
56
6,
 1
66
7)
 
16
  
(9
, 1
8)
 
15
72
 §
§ 
(1
52
1,
 1
61
0 
20
 (1
5,
26
) 
pH
 
N
A
 
N
A
 
23
76
  
(2
11
6,
 2
63
5)
 
7.
33
  
(7
.3
0,
 7
.3
8)
 
25
09
  
(2
28
3,
 2
64
8)
 
7.
38
  
(7
.3
3,
 7
.4
1)
 
N
A
 
N
A
 
B
ic
ar
bo
na
te
 (m
M
) 
N
A
 
N
A
 
21
77
  
(2
19
9,
 2
39
5)
 
31
  
(2
9,
 3
2)
 
22
43
  
(2
20
2,
 2
32
0)
 
33
  
(3
1,
 3
5)
 
N
A
 
N
A
 
 To
 d
et
er
m
in
e 
th
e 
cr
iti
ca
l c
ar
di
ac
 in
de
x 
va
lu
e 
(C
I cr
it)
 fo
r e
ac
h 
va
ria
bl
e,
 w
e 
ca
rr
ie
d 
ou
t d
ua
l l
in
e 
re
gr
es
si
on
 a
na
ly
se
s f
or
 e
ac
h 
va
ria
bl
e 
on
 e
ve
ry
 
an
im
al
 a
nd
 in
 e
ac
h 
or
ga
n 
st
ud
ie
d.
 T
he
 th
re
sh
ol
d 
va
lu
es
 o
f t
he
 v
ar
ia
bl
es
 a
re
 th
os
e 
fo
un
d 
at
 th
e 
co
rr
es
po
nd
in
g 
C
I cr
it. 
Ti
ss
ue
 P
C
O
2 i
n 
m
us
cl
e 
an
d 
in
te
st
in
e 
w
as
 si
gn
ifi
ca
nt
ly
 h
ig
he
r t
ha
n 
in
 k
id
ne
y 
an
d 
liv
er
 (
, p
 <
 0
.0
1)
. M
us
cl
e 
la
ct
at
e 
w
as
 si
gn
ifi
ca
nt
ly
 lo
w
er
 th
an
 in
 o
th
er
 o
rg
an
s (
#,
 p
 <
 0
.0
2)
. 
LP
 ra
tio
 (§
, p
 <
 0
.0
1)
 w
as
 si
gn
ifi
ca
nt
ly
 lo
w
er
 in
 a
ll 
or
ga
ns
 c
om
pa
re
d 
to
 la
ct
at
e 
an
d 
PC
O
2. 
G
ly
ce
ro
l (
§§
, p
 <
 0
.0
1)
 w
as
 si
gn
ifi
ca
nt
ly
 lo
w
er
 th
an
 L
P 
ra
tio
 in
 a
ll 
or
ga
ns
 te
st
ed
. T
o 
te
st
 fo
r s
ig
ni
fic
an
t d
iff
er
en
ce
s b
et
w
ee
n 
th
e 
cr
iti
ca
l C
I v
al
ue
s, 
w
e 
ap
pl
ie
d 
K
ru
sk
al
-W
al
lis
 O
ne
 W
ay
 A
na
ly
si
s o
f 
V
ar
ia
nc
e 
on
 R
an
ks
, a
nd
 th
e 
po
st
-h
oc
 S
tu
de
nt
-N
eu
m
an
 K
eu
ls
 (S
N
K
) t
es
t f
or
 a
 m
ul
tip
le
 c
om
pa
ris
on
 o
f a
ll 
th
e 
gr
ou
ps
. 
 
T
ab
le
 2
: R
at
e 
of
 in
cr
ea
se
 in
 P
C
O
2 a
nd
 la
ct
at
e 
un
de
r 
ae
ro
bi
c 
an
d 
an
ae
ro
bi
c 
co
nd
iti
on
s 
Pa
ra
m
et
er
 
M
us
cl
e 
K
id
ne
y 
L
iv
er
 
In
te
st
in
e 
 
A
er
ob
ic
 
A
na
er
ob
ic
 
A
er
ob
ic
 
A
na
er
ob
ic
 
A
er
ob
ic
 
A
na
er
ob
ic
 
A
er
ob
ic
 
A
na
er
ob
ic
 
dP
C
O
2/d
T
  
(k
Pa
 h
ou
r-1
) 
0.
61
 
 
(0
.4
5,
 0
.8
0)
 
3.
70
 §
 
(3
.0
7,
 4
.1
2)
 
0.
30
 
 
(0
.2
7,
 0
.3
7)
 
8.
47
 §
 
(6
.0
8,
 1
3.
02
) 
0.
28
 
 
(0
.1
0,
 0
.4
2)
 
4.
35
 §
 
(3
.4
7,
 6
.1
5)
 
0.
72
 
 
(0
.5
6,
 0
.8
2)
 
9.
25
 §
 
(7
.3
8,
 1
0.
70
) 
dL
ac
ta
te
/d
T
  
(m
M
 h
ou
r-1
) 
0.
00
  
(0
.0
0,
 0
,0
1)
 
6.
65
 §
 
(6
.4
7,
 8
.9
8)
 
0.
11
  
(0
.0
6,
 0
.1
7)
 
6.
05
 §
 
(4
.9
2,
 7
.1
5)
 
0.
01
  
(0
.0
0,
 0
.0
7)
 
6.
80
 §
 
(5
.4
7,
 7
.2
3)
 
0.
03
  
(0
.0
2,
 0
.1
7)
 
4.
11
 §
 
(2
.5
3,
 5
.5
7)
 
 A
ll 
va
lu
es
 fo
r a
er
ob
ic
 d
PC
O
2/d
T 
w
er
e 
si
gn
ifi
ca
nt
ly
 h
ig
he
r t
ha
n 
ze
ro
 (
, p
 <
 0
.0
5)
 w
he
re
as
 n
on
e 
of
 th
e 
ae
ro
bi
c 
dL
ac
ta
te
/d
T 
w
as
. A
er
ob
ic
 
dL
ac
ta
te
/d
T 
in
 th
e 
ki
dn
ey
, h
ow
ev
er
, i
nc
re
as
ed
, b
ut
 it
 d
id
 n
ot
 re
ac
h 
si
gn
ifi
ca
nc
e 
(p
 =
 0
.0
9)
. A
ll 
va
lu
es
 fo
r b
ot
h 
pa
ra
m
et
er
s w
er
e 
si
gn
ifi
ca
nt
ly
 
hi
gh
er
 in
 th
e 
an
ae
ro
bi
c 
ph
as
e 
co
m
pa
re
d 
to
 th
e 
ae
ro
bi
c 
(§
, p
 <
 0
.0
1)
. D
at
a 
ar
e 
pr
es
en
te
d 
as
 m
ed
ia
n 
an
d 
in
te
rq
ua
rti
le
 ra
ng
es
 (2
5%
, 7
5%
). 
To
 te
st
 
fo
r s
ig
ni
fic
an
t d
iff
er
en
ce
s b
et
w
ee
n 
th
e 
gr
ou
ps
, w
e 
ap
pl
ie
d 
K
ru
sk
al
-W
al
lis
 O
ne
 W
ay
 A
na
ly
si
s o
f V
ar
ia
nc
e 
on
 R
an
ks
, a
nd
 th
e 
po
st
-h
oc
 S
tu
de
nt
-
N
eu
m
an
 K
eu
ls
 (S
N
K
) t
es
t f
or
 a
 m
ul
tip
le
 c
om
pa
ris
on
 o
f a
ll 
th
e 
gr
ou
ps
. 
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